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ABSTRACT 
Extracellular Ubiquitin: Role in Cardiac Myocyte Apoptosis and Myocardial Remodeling 
by 
Christopher Ray Daniels  
 
Activation of sympathetic nervous system is a key component of myocardial remodeling that 
generally occurs following ischemia/reperfusion (I/R) injury and myocardial infarction. It 
induces cardiac myocyte apoptosis and myocardial fibrosis, leading to myocardial dysfunction. 
Intracellular ubiquitin (UB) regulates protein turnover by the UB-proteosome pathway. The 
biological functions of extracellular UB in the heart remain largely unexplored. Previously, our 
lab has shown that β-adrenergic receptor (β-AR) stimulation increases extracellular UB levels, 
and extracellular UB inhibits β-AR-stimulated apoptosis in adult rat ventricular myocytes 
(ARVMs). This study explores the role of extracellular UB in myocyte apoptosis, fibroblast 
phenotype and function, and myocardial remodeling following β-AR stimulation and I/R injury. 
First, left ventricular (LV) structural and functional remodeling was studied 7 days after chronic 
β-AR-stimulation in the presence or absence of UB infusion. Echocardiographic analyses 
showed UB infusion decreases β-AR-stimulated increases in percent fractional shortening and 
ejection fraction. It decreased cardiac myocyte apoptosis and myocardial fibrosis. UB activated 
Akt, and inhibition of Akt inhibited β-AR-stimulated increases in matrix metalloproteinase-2 
expression. Second, using cardiac fibroblasts, we provide evidence that extracellular UB 
interacts with the cell surface and co-immunoprecipitates with CXCR4. UB treatment increased 
expression of α-smooth muscle actin (myofibroblast marker), and induced rearrangement of actin 
into stress fibers. It inhibited lamellopodia and filopodia formation, and cell migration into the 
3 
 
wound. Third, using isolated mouse heart and I/R injury as a model, we provide evidence that 
UB treatment decreases I/R-mediated increases in infarct size. UB treatment improved functional 
recovery of the heart as measured by increased % LV developed pressure. Activation of 
proapoptotic proteins, p-STAT-1 and caspase-9, was significantly lower in UB I/R hearts versus 
I/R alone. In ARVMs, UB treatment decreased simulated I/R-induced apoptosis. It activated Akt 
(anti-apoptotic kinase) and inhibited activation of GSK-3β (pro-apoptotic kinase). It decreased 
I/R-induced oxidative stress and protected anoxia-induced mitochondrial polarization. In 
fibroblast and ARVMs, CXCR4 antagonism negated the effects of UB, while mutated UBs 
(unable to interact with CXCR4) had no effect. Thus, extracellular UB, most likely acting via 
CXCR4, modulates myocardial remodeling with effects on heart function, fibroblast phenotype 
and function and myocyte apoptosis.  
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CHAPTER 1 
INTRODUCTION 
Cardiovascular disease is the leading cause of death in men and women in the United 
States and is responsible for over 29% of all deaths world-wide. Cardiovascular disease is the 
number 1 cause of deaths among people over the age of 65 years and the number 2 cause of 
deaths in ages 45-64 years. The disease kills more women every year than cancer and stroke.  
Over one million people in the United States sustain a myocardial infarction (MI), or 
heart attack, every year. An MI occurs when the supply of blood, oxygen, and nutrients to an 
area of the heart muscle is blocked. This results in a decrease in function of the heart and causes 
sudden death in about half of all victims. For those who survive, the affected heart muscle will 
be replaced by scar tissue. However, 19% of women and 26% of men die within 1 year post-MI. 
The estimated annual incidence of MI is 515,000 new attacks and 205,000 recurrent attacks, and 
the average age at first MI is 64.9 years in men and 72.3 years for women.  (Statistic provided by 
the American Heart Association and the National Heart Lung and Blood Institute.)  
 
Cardiac Remodeling 
Myocardial remodeling refers to the changes in the structure and function of the heart that 
commonly occur as a result of heart disease. Adverse myocardial remodeling associates with 
poor patient outcomes in the context of ischemic heart disease and/or MI, myocardial 
hypertrophy, and other cardiomyopathic disease states. Cardiac remodeling generally associates 
with a number of cellular changes including loss of myocytes due to apoptosis (Sharov and 
others 1996; Olivetti and others 1997), fibroblast proliferation, and fibrosis (Weber and others 
1990; Villarreal and others 1993). These changes clinically manifest as changes in size, shape, 
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and function of the heart after myocardial injury (Kehat and Molkentin 2010). The remodeling 
process acts as a compensatory mechanism in early stage but becomes deleterious. Cardiac 
myocyte apoptosis plays a role in MI (Cohn and others 2000).  Apoptosis, programmed cell 
death, is a highly organized process. After MI or ischemic event, left ventricular (LV) 
dysfunction occurs, in part, as a result of ongoing cardiac myocyte apoptosis (Sharov and others 
1996). Cardiac myocyte apoptosis occurs at an increased rate after injury due to ischemia, 
reperfusion, and MI (Olivetti and others 1997).  
Fibrosis is the excess production and accumulation of extra cellular matrix (ECM) 
structural proteins and results in enhanced stiffness of the myocardium and impedes ventricular 
contraction and relaxation, leading to distorted architecture and function of the heart (Fan and 
others 2012). Cardiac fibroblast play a critical role in the remodeling process of the heart that 
occurs in response to MI, hypertension, and heart failure (Souders and others 2009). Activated 
fibroblasts are critical in both the reparative and fibrotic processes. In normal tissues resident 
fibroblasts are quiescent, producing limited amounts of extracellular matrix proteins and 
exhibiting few actin-associated cell-matrix and cell-cell contacts (Tomasek and others 
2002).Tissue injury induces alterations in the microenvironment, resulting in differentiation of 
fibroblasts into myofibroblasts (Hinz 2007). The matrix metalloproteinases (MMPs) and the 
endogenous tissue inhibitor of metalloproteinase inhibitors (TIMPS) play a major role in 
remodeling of the ECM. Plasma levels of MMP2 and MMP9 are elevated in MI patients, but 
only the MMP9 levels exhibit a biphasic profile that peaked within the first 12 hours and then 
fall to a plateau (Webb and others 2006). For example, mice with global deletion of MMP-9 
develop normally in the absence of pathophysiological stress, but they show a reduction in the 
degree of ventricular dilation and adverse matrix remodeling after myocardial infarction 
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(Ducharme and others 2000). Similarly, MMP-2–null mice exhibited a reduction in the rupture 
rate after myocardial infarction (Matsumura and others 2005). However, pressure overload 
induced by aortic constriction in MMP-2–null mice have shown blunting of the hypertrophic 
response (Matsumura and others 2005). Therefore, gene deletion of either MMP-9 or MMP-2 is 
associated with significant effects on myocardial matrix remodeling, fibrosis, and whole organ 
geometry (Kehat and Molkentin 2010). These findings support a mechanistic role for both MMP-
2 and -9 in adverse myocardial remodeling processes.   
 
Ischemia/Reperfusion and Myocardial Infarction  
Myocardial ischemia is the reduction of blood flow and nutrients, and reperfusion is the 
return of blood flow to the myocardium. If the period of acute myocardial ischemia is prolonged, 
more than 20min, a “wave front” of cardiomyocyte death occurs in endocardium and extends 
over time to the epicardium (Reimer and others 1977). Many biochemical and metabolic changes 
occur within the myocardium during ischemia. The absence of oxygen prevents oxidative 
phosphorylation, leading to mitochondrial membrane depolarization, ATP depletion, and 
inhibition of myocardial contractile function (Hausenloy and Yellon 2013).  
      Reperfusion is a prerequisite for the survival of ischemic myocardium. Reperfusion or 
restoration of blood flow to the ischemic heart limits infarct size and reduces mortality. 
However, reperfusion can also result in additional cardiac damage, referred as reperfusion injury.  
Reperfusion injury is a complex process that includes rapid restoration of physiological pH, 
oxidative stress, intracellular Ca
++
 overload, and mitochondrial damage. During reperfusion, 
physiological pH is rapidly restored by the removal of lactate and the activation of the Na
+
-H
+ 
exchanger as well as the Na
+
-HCO
-
 symporter (Hausenloy and Yellon 2013). The change in pH 
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leads to cardiomyocyte apoptosis by allowing mPTP opening and cardiomyocyte 
hypercontracture in the first few minutes of reperfusion (Lemasters and others 1996). Shortly 
after reperfusion the electron transport chain is reactivated causing an increase in reactive 
oxygen species (ROS). ROS is also produced by xanthine oxidase in endothelial cells and 
NADPH oxidase released during an influx of neutrophils (Brechard and Tschirhart 2008; Frey 
and others 2009). This leads to oxidative damage of DNA, proteins, and the sarcoplasmic 
reticulum causing intracellular Ca
++
 overload (Dejeans and others 2010). Intracellular and 
mitochondrial Ca
++ 
overload starts during ischemia. However, reperfusion accelerates the process 
due to disruption of the plasma membrane, oxidative stress-induced damage to the sarcoplasmic 
reticulum, and mitochondrial re-energization (Hausenloy and Yellon 2013; Rodrigo and others 
2013). Mitochondrial re-energization is the recovery of the mitochondrial membrane potential 
that causes the entry of Ca
++ 
into the mitochondria and induces the opening of the mPTP (Fig 
1.1).  A severe microvascular dysfunction may limit adequate perfusion after reperfusion. This 
‘no flow’ phenomenon occurs in about 30% of patients and associates with an increased 
incidence of acute MI, myocardial rupture, and death (Moens and others 2005).  
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Figure 1.1. Cascade of Events Due to Ischemia/Reperfusion Injury. ROS, reactive oxygen 
species; mPTP, mitochondrial membrane permeability transition pore. 
 
 
β-Adrenergic Receptor Stimulation and Heart Disease 
 Increased sympathetic nerve activity to the myocardium is a central feature in patients 
with heart failure (Hasking and others 1986), and chronic exposure to catecholamines is known 
to be toxic to cardiac myocytes (Rona 1985). Chronic β-adrenergic receptor (β-AR) stimulation 
potentiates myocardial ischemia/reperfusion (I/R) injury (Hu and others 2006). Initial release of 
catecholamines by the sympathetic nervous system exerts important tonic effects on the biology 
of cardiac myocytes leading to increased contractility. However, chronic increase in sympathetic 
activity is known to have adverse effects in the heart. The efficacy of β-AR antagonist in 
improving the clinical outcome as well as benefit in long-term morbidity and mortality of 
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patients with chronic heart failure (Bristow 2000)
 
has confirmed the importance of sympathetic 
nerve activity in the pathological remodeling, a process that leads to progressive left ventricular 
dilation and contractile dysfunction. Norepinephrine, a primary neurotransmitter of sympathetic 
nervous system, signals via its interaction with α- and β-AR, a family of G protein-coupled 
receptors. Specific stimulation of β-AR using norepinephrine or isoproterenol (β-AR agonist) 
induces apoptosis in cardiac myocytes in vitro and in vivo (Singh and others 2001; Goldspink 
and others 2004; Krishnamurthy and others 2007). Increased myocyte apoptosis may influence 
the development of heart failure. 
 
β-AR-Stimulation and Cardiac Myocyte Apoptosis 
Stimulation of -AR induces apoptosis in cardiac myocytes in vitro and in vivo 
(Shizukuda and others 1998; Iwai-Kanai and others 1999; Zaugg and others 2000; Singh and 
others 2001).  Three subtypes of β-AR have been identified (β1, β2, β3) (Hadcock and Malbon 
1993), and all 3 types are expressed on cardiac myocytes (Devic and others 2001). β1-AR is the 
most abundant receptor type in cardiac myocytes. However, the ratio of β1 to β2-AR varies 
among species and under various pathophysiological states (Bristow 2000). Both β1- and β2-AR 
couple to the stimulatory G protein (Gαs) (Amin and others 2011). This coupling leads to 
activation adenylyl cyclase and production of cAMP a common second messenger. β2-AR can 
also couple to a Gi, a different heterodimeric G-protein whose Gα subunit inhibits adenylyl 
cyclase and synthesis of cAMP. However, this coupling may require phosphorylation of β2-AR 
by cAMP-dependent protein kinase A (Daaka and others 1997). Stimulation of β1-AR-Gs and 
activation of PKA induces myocyte apoptosis (Communal and others 1999; Shizukuda and 
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Buttrick 2002), while stimulation of β2-AR-Gi and activation of phosphatidylinositol 3-kinase 
(PI3-kinase) and Akt inhibit apoptosis (Xiao 2001).  
Mitogen activated protein kinases (MAPKs), a large family of serine-threonine kinases, 
have important functions as mediators of intracellular signal transduction (Figure 1.2). Three 
subgroups of MAPKs have been identified: c-jun N-terminal kinases (JNKs), p38 kinase, and 
ERK1/2 (Cargnello and Roux 2011). β-AR stimulation has been shown to activate these 3 
subgroups of MAPKs (Communal and others 2000). Activation of JNKs plays a proapoptotic 
role (Remondino and others 2003). Activation of p38 kinase plays a protective role in β-AR-
stimulated myocyte apoptosis, and inhibition of ERK1/2 using PD98059 had no effect on β-AR-
stimulated apoptosis (Communal and others 2000). Superoxide dismutase/catalase-mimetics or 
catalase overexpression inhibited JNK activation and β-AR-stimulated apoptosis (Remondino 
and others 2003). Inhibition of mitochondrial permeability transition pore opening or caspase 
activation decreases β-AR-stimulated apoptosis (Remondino and others 2003). These studies 
suggest that β-AR-stimulated apoptosis in adult rat ventricular myocytes involves reactive 
oxygen species/JNK-dependent activation of the mitochondrial death pathway. β-AR stimulation 
also activates glycogen synthase kinase-3β (GSK-3β), and activation of GSK-3β plays a 
proapoptotic role in β-AR-stimulated apoptosis via the involvement of mitochondrial death 
pathway (Novikoff and others 1975). Adenoviral-mediated overexpression of constitutively 
active GSK-3β increased JNK phosphorylation, suggesting that GSK-3β may also act upstream 
in the activation of JNKs (Singh and others 2010).    
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Figure 1.2 Summary Diagram Illustrating Signaling Pathways Involved in β-AR-Stimulated 
Cardiac Myocyte Apoptosis. AR: adrenergic receptors; JNKs: c-Jun-N-terminal kinase; GSK-3β: 
glycogen synthase kinase-3β; ROS: reactive oxygen species; PKA: protein kinase A; AC: 
adenylyl cyclase; Gs: stimulatory G protein; Gi: inhibitory G protein; ATP: adenosine 
triphosphate; cAMP: cyclic adenosine monophosphate; CaMKIIδ: calcium calmodulin kinase 
IIδ; PI-3K: phosphatidylinositol 3-kinase. (Source Amin 2011)      
 
β-AR-Stimulation and Myocardial Fibrosis 
 In heart failure the sympathetic system is overactivated and leads to formation of cardiac 
fibrosis, which contributes to the aggravation of cardiac function (Bos and others 2005). Cardiac 
fibrosis results from proliferation of interstitial fibroblasts and concomitant increased 
biosynthesis of ECM components. Isoproterenol (β-AR agonist) has been shown to produce 
increased fibrosis and hypertrophy (Krishnamurthy and others 2007). Greater cardiac fibrosis in 
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Brown Norway rats treated with isoproterenol correlates with the early and higher expression of 
proinflammatory factors  (Copaja and others 2008). Isoproterenol-induced myocardial fibrosis is 
initiated by the appearance of interstitial edema and fibrillar collagen disruption and is followed 
soon thereafter by the formation of thinner collagen fibers that extend across muscle fibers and 
into which thicker collagen fibers become entwined in a crisscrossing pattern. Once formed, this 
mesh of collagen fibers encircles cardiac muscle (Pick and others 1989). It is also interesting to 
note that stimulation of β-AR increases expression and activity of MMP-2 and MMP-9 in cardiac 
myocytes and in the heart (Menon and others 2005; Krishnamurthy and others 2007). Thus, 
deposition of fibrosis may represent a complex function of both collagen synthesis and 
degradation.  
 
Ubiquitin 
 Ubiquitin is a small heat-stable protein (~ 8.5 kDa) found in all eukaryotic cells 
(Ciechanover and others 1980; Ozkaynak and others 1984). Its amino acid sequence is highly 
conserved between animal species with only 2-3 amino acid residues differing between yeast and 
human (Wilkinson and others 1986). Ubiquitin is a well-known posttranslational protein 
modifier and covalent ligation of ubiquitin to intracellular proteins is known as ubiquitination or 
ubiquitylation. This process is catalyzed by ubiquitin protein ligase systems (Bairoch 2000). The 
ubiquitin protein ligase system consist of 3 enzymes and leads to the degradation of proteins 
through the ubiquitin proteosome pathway (Hershko and Ciechanover 1998). In the ubiquitin-
proteosome pathway ubiquitination is the signal for degradation of the target protein by the 26S 
proteosome (Hershko and Ciechanover 1998; Schwartz and Ciechanover 2009). Ubiquitination 
leads to a polyubiquitin tag and is required for protein degradation by the proteosome (Hicke 
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2001). Following phosphorylation, ubiquitination is the second most common posttranslation 
protein modification (Weissman 2001; Haataja and others 2002).  
 Ubiquitin is a normal plasma protein. Normal ubiquitin concentrations in human plasma 
and serum lies in the low nanomolar range (<10nM ; <100ng/mL) (Okada and others 1993; 
Okada and others 1995). Ubiquitin is also detectable in cerebral spinal fluid (CSF), 
bronchoaveolar lavage fluid (BALF), seminal plasma, and urine. Ubiquitin concentrations are 3 
to 5 folds lower in CSF than what is found in circulation. However, normal urine concentrations 
are slightly lower than serum concentrations (Majetschak and others 2003; Pisitkun and others 
2004). Higher ubiquitin concentrations in systemic circulation have been reported in multiple 
diseases such as; allergic, autoimmune, infections, and kidney failure (Asseman and others 1994; 
Okada and others 1995; Akarsu and others 2001b; Majetschak and others 2003). Extracellular 
ubiquitin is proposed to have pleotropic effects on hematopoiesis, leukocytes, and platelets and 
possess antimicrobial activity (Kagan and others 1977; Kagan and others 1979; Pancre and 
others 1991; Kieffer and others 2003).  
 The G protein–coupled receptor CXC chemokine receptor (CXCR)4 is abundantly 
expressed in immune cells and tissues, including cardiac fibroblast (Hu and others 2007). 
CXCR4 plays an important role in a variety of biological processes and is suggested to be 
involved in the pathophysiology of various disease processes such as cancer, HIV, ischemic 
myocardial injury, and angiogenesis (Tripathi and others 2013). Stromal derived factor-1α (SDF-
1α) is the cognate ligand for CXCR4 that is implicated in homing of hematopoietic stem cells 
during wound repair (Chu and others 2010). SDF-1α is shown to have cardioprotective effects 
against ischemia/reperfusion injury by promoting antiapoptotic program (Hu and others 2007). 
Interestingly, CXCR4 is identified as a receptor for UB in THP1 leukemia cell line (Saini and 
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others 2010). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini et al. provide 
evidence that the ubiquitin-CXCR4 interaction follows a 2-site binding mechanism in which the 
hydrophobic surfaces surrounding Phe-4 and Val-70 are important for receptor binding, whereas 
the flexible C terminus facilitates receptor activation (Saini and others 2011).  
 
Extracellular UB and β-AR-Stimulated Myocyte Apoptosis 
As discussed above, β-AR stimulation induces apoptosis in adult cardiac myocytes. 
However, β-AR stimulation induces apoptosis only in a fraction (∼15–20%) of myocytes, 
although all the cells are exposed to the same stimulus. Previously, a search to identify survival 
factor(s) secreted or released by myocytes that protect 80–85% of cells from apoptosis (in our 
lab) using 2-dimensional gel electrophoresis followed by MALDI TOF and MS/MS, led to 
identification of UB in the conditioned media of myocytes treated with β-AR agonist 
(isoproterenol) (Singh and others 2010). Inhibition of β1-AR and β2-AR subtypes inhibited β-
AR-stimulated increases in extracellular levels of UB, whereas activation of adenylyl cyclase 
using forskolin mimicked the effects of β-AR stimulation. Pretreatment with UB inhibited β-AR-
stimulated increases in apoptosis. Inhibition of phosphoinositide 3-kinase using wortmannin and 
LY-294002 prevented antiapoptotic effects of extracellular UB. UB pretreatment inhibited β-
AR-stimulated activation of GSK-3β and JNK and increases in the levels of cytosolic 
cytochrome c. The use of methylated UB suggested that the antiapoptotic effects of extracellular 
UB are mediated via monoubiquitination. Together, these studies suggested that β-AR 
stimulation increases levels of UB in the conditioned media. Extracellular UB plays a protective 
role in β-AR-stimulated apoptosis, possibly via the inactivation of GSK-3β/JNK and 
mitochondrial pathways (Singh and others 2010). 
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Specific Aims  
 The overall goal of the present study was to further understand the role extracellular 
ubiquitin plays in cardiac myocyte apoptosis, the signaling mechanisms involved, and the 
implications in the processes of cardiac remodeling. We hypothesized that extracellular ubiquitin 
modulates cardiac myocyte apoptosis and fibroblast phenotype and function, thereby modulating 
chronic β-AR receptor-stimulated and I/R-induced myocardial remodeling. The specific aims of 
the study were as follows: 1) investigate the in vivo role of exogenous ubiquitin in β-AR-
stimulated myocardial remodeling with effects on LV function, fibrosis, and myocyte apoptosis; 
2) study the role of extracellular ubiquitin in modulation of cardiac fibroblast phenotype and 
function; and 3) determine the effect of extracellular ubiquitin on the process of myocardial I/R 
injury at the cellular and tissue levels. 
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Abstract 
β-adrenergic receptor (β-AR) stimulation increases extracellular ubiquitin (UB) levels, and 
extracellular UB inhibits β-AR-stimulated apoptosis in adult cardiac myocytes. This study 
investigates the role of exogenous UB in chronic β-AR-stimulated myocardial remodeling. L-
isoproterenol (ISO; 400µg/kg/h) was infused in mice in the presence or absence of UB (1g/g/h). 
Left ventricular (LV) structural and functional remodeling was studied 7 days after infusion. UB 
infusion enhanced serum UB levels. In most parts, UB alone had no effect on morphometric or 
functional parameters. Heart weight-to-body weight ratios were increased to a similar extent in 
ISO and UB+ISO groups. Echocardiographic analyses showed increased percent fractional 
shortening, ejection fraction and LV circumferential stress and fiber shortening velocity in ISO 
group. These parameters were significantly lower in UB+ISO vs ISO. Isovolumic contraction 
and relaxation times, and ejection time were significantly lower in ISO vs UB+ISO. The increase 
in the number of TUNEL-positive myocytes and fibrosis was significantly higher in ISO vs 
UB+ISO. Activation of Akt was higher, while activation of GSK-3β and JNKs was lower in 
UB+ISO vs ISO. Expression of MMP-2, MMP-9 and TIMP-2 was higher in UB+ISO vs ISO. In 
isolated cardiac fibroblasts, UB enhanced expression of MMP-2 and TIMP-2 in the presence of 
ISO. Neutralizing UB antibodies negated the effects of UB on MMP2 expression, while 
recombinant UB enhanced MMP-2 expression. UB activated Akt, and inhibition of Akt inhibited 
UB+ISO-mediated increases in MMP-2 expression. Thus, exogenous UB plays an important role 
in β-AR-stimulated myocardial remodeling with effects on LV function, fibrosis and myocyte 
apoptosis.  
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Introduction 
 Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells. 
The most important intracellular function of UB is to regulate protein turnover by the ubiquitin-
proteasome pathway (15). The ubiquitin-proteasome pathway may regulate receptor 
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in 
cardiac myocytes (56). UB is a normal constituent of plasma. Elevated levels of UB are 
described in the serum or plasma of patients with parasitic and allergic diseases (4), alcoholic 
liver disease (48), type 2 diabetes (1), β2-Microglobulin amyloidosis (34) and chronic 
hemodialysis patients (2). Patients with traumatic brain injury are shown to have increased UB 
levels in the cerebrospinal fluid (28). Extracellular UB is proposed to have pleiotropic functions 
including regulation of immune response, anti-inflammatory and neuroprotective activities (27; 
29; 36), as well as growth regulation and apoptosis control in hematopoetic cells (9). The 
biological functions of extracellular UB in the heart remain largely unexplored. Specifically, the 
role of exogenous UB in myocardial remodeling has not yet been investigated. 
 Sympathetic nerve activity increases in the heart during cardiac failure. Prolonged 
stimulation of the β-adrenergic neurohormonal axis contributes to the progression of heart failure 
and mortality in animal models and human patients (13; 43). Stimulation of -adrenergic 
receptor (β-AR) increases expression and activity of matrix metalloproteinase (MMP-2 and 
MMP-9) in cardiac myocytes in vitro and in vivo (23; 31). It induces apoptosis in cardiac 
myocytes in vitro and in vivo (19; 42; 43; 55). b-AR-stimulated apoptosis in adult rat ventricular
 
myocytes (ARVMs) is demonstrated to occur via the GSK-3β-/JNK-dependent mitochondrial 
death pathway (30; 39). Recently, we provided evidence that stimulation of β-AR increases 
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extracellular levels of UB in ARVMs, and extracellular UB plays a protective role in β-AR-
stimulated apoptosis via the inactivation of GSK-3β and JNKs pathways (44).   
 Here, we investigated the in vivo role of exogenous UB in cardiac myocyte apoptosis and 
myocardial remodeling following chronic β-AR stimulation in mice. We report that exogenous 
UB plays an important role in β-AR-stimulated myocardial remodeling with effects on left 
ventricular function, fibrosis and myocyte apoptosis. It may inhibit myocyte apoptosis via the 
activation of Akt and inactivation of GSK-3β and JNKs, while inhibits fibrosis by modulating 
expression and activity of MMPs and TIMPs. 
 
Methods and Material 
Experimental Animals  
  The investigation conforms with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
The animal protocol was approved by the University Committee
 
on Animal Care. Animals were 
anesthetized using a mixture of isoflurane (2.5%) and oxygen (0.5 l/min) and the heart was 
excised following a bilateral cut in the diaphragm. Mice were euthanized by exsanguination. The 
studies were performed using male ICR mice (25-30 g; purchased from Harlan Lab.).   
 
Mice Treatment  
Mice were randomly assigned to 4 groups (sham, ISO, UB+ISO and UB). The mice in 
UB+ISO and UB groups received intraperitoneal injection of UB (1 g/g; U6253; Sigma) 1h 
prior to pump implantation. The mice were infused with ISO (isoproterenol; 400 g/kg/h; ISO 
group), UB+ISO (1 g/g/h+400 g/kg/h; UB+ISO group) and UB (1µg/g/h; UB group) at the 
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rate of 1.0 l/h for 7 days using mini-osmotic pumps (Alzet Corp.). L-isoproterenol and UB were 
dissolved
 
in acidified isotonic saline (0.001 N HCl). Sham animals were infused with acidified 
isotonic
 
saline solution. The dose of ubiquitin and ISO were selected based on previously 
published reports (14; 23; 42).  
 
Echocardiography  
Transthoracic two-dimensional M-mode echocardiogram and pulsed wave Doppler 
spectral tracings were obtained using a Toshiba Aplio 80 Imaging System (Tochigi, Japan) 
equipped with a 12 MHz linear transducer (12; 23). Echocardiographic procedures were 
performed prior to and 7 days after implantation of pumps. The animals were anesthetized during 
procedure using a mixture of isoflurane (1.5%) and oxygen (0.5 l/min), and their body 
temperature maintained at ~37°C using a heating pad. M-mode tracings were used to measure 
LV end-systolic diameter (LVESD) and end-diastolic diameter (LVEDD). Percent fractional 
shortening (%FS) and ejection fraction (EF%) were calculated as described (12; 23). Doppler 
tracings of mitral and aortic flow were used to measure isovolumic relaxation time (IVRT), 
isovolumic contraction time (IVCT) and ejection time (ET). LV circumferential stress and fiber 
shortening velocity (Vcf) was calculated as = LVEDD – LVESD / LVEDD x LVET, where 
LVEDD and LVESD are LV diastolic and systolic diameters, respectively, and LVET is LV 
ejection time (38). All echocardiographic assessments were performed by the same investigator 
blinded to the treatments. A second person also performed measurements on a separate occasion 
using the same recordings with no significant differences in interobserver variability.  
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Morphometric Analyses   
Animals were euthanized and the hearts were arrested
 
in diastole using KCl (30 mM) 
followed by perfusion fixation
 
with 10% buffered formalin.  Cross sections (4 µm thick) were 
stained with Masson’s trichrome for the measurement of fibrosis using Bioquant image analysis 
software (Nashville, TN). 
 
Measurement of Serum UB Levels 
Serum UB levels, 7 days after ISO-infusion, were measured using ELISA kit (Novatein 
Biosciences).  
 
Myocyte Cross-Sectional Area  
Heart sections (4 µm thick) were deparaffinized and stained with TRITC-labeled wheat 
germ agglutinin (WGA). The sections were visualized using fluorescent microscopy (20X; 
Nikon) and images
 
were recorded using Retiga 1300 color-cooled camera. Suitable area of the 
sections was defined as the one with nearly circular capillary profiles. 
 
TUNEL Staining  
To measure apoptosis, terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) staining followed by Hoechst 33258 staining was carried out on 4 µm-thick 
paraffin-embedded sections as per manufacturer’s instructions (Cell death detection assay kit, 
Roche). To identify apoptosis associated with cardiac myocytes, the sections were 
immunostained using -sarcomeric actin antibodies (1:50; 5C5 clone, Sigma, St Louis, MO). 
Hoechst 33258 (10 µM; Sigma, St Louis, MO) staining was used to count the total number of 
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nuclei. TUNEL-positive nuclei that were clearly seen within cardiac myocytes were counted. 
The number of apoptotic cardiac myocyte nuclei was counted and index of apoptosis was 
calculated as the percentage of apoptotic myocyte nuclei/total number of nuclei. 
 
Fibroblast Isolation and Treatment  
Adult rat cardiac fibroblasts were isolated as described (53). The cells were grown to 
confluence and serum-starved for 48 h before use. First and second passage cells were used for 
all the experiments. The cells were pretreated with UB (10 µg/ml; Sigma) for 30 min followed 
by treatment with ISO for indicated time points. To neutralize effects of UB, cells were 
pretreated with anti-UB antibodies (5 µg/ ml; U5379; Sigma) for 30 min. To verify effects of 
UB, cells were pretreated with recombinant UB (rUB; 10 or 100 µg/ml; Boston Biochem) for 30 
min followed by treatment with ISO for 48 h. To inhibit Akt, cells were pretreated with MK-
2206 (1 μM; Chemie Tek) for 30 min, then with UB (10 µg/ml) for 30 min followed by 
treatment with ISO.     
 
Western Analysis  
LV tissue lysates were prepared in RIPA buffer [10 mM Tris-HCl (pH 7.2), 158 mM 
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium 
orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride] using a tissue homogenizer. Cell lysates 
were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X-100, and 1 mM 
phenylmethylsulfonyl fluoride]. Equal amounts of total proteins (70 μg from tissue lysates or 20 
µg from cell lysates) were resolved on 10% SDS-polyacrylamide gels. The proteins were 
transferred onto PVDF membrane. The blots were then probed with primary antibodies directed 
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against p-Akt (1:1000; Cell Signaling Tech.), p-GSK-3β (1:1000; Cell Signaling Tech.), p-JNKs 
(1:1000; Millipore), p-ERK1/2 (1:2000; Cell Signaling Tech.), MMP-2 (1:5000; Millipore), 
MMP-9 (1:5000; Millipore), or TIMP-2 (1:1000; Santa Cruz) and appropriate secondary 
antibodies. Membranes were then stripped and probed with Akt, GSK-3β, JNKs, ERK1/2, actin 
(Chemicon) or GAPDH (Santa Cruz) antibodies to normalize protein loading. Band intensities 
were quantified using Kodak photo documentation system (Eastman Kodak Co.).  
 
In-gel Zymography  
Gelatin in-gel zymography in the concentrated conditioned media of fibroblasts (2 µg) or 
LV (50 µg) lysates was performed as described (53). Clear and digested regions representing 
MMP-2 activity were quantified using a Kodak documentation system.  
 
Statistical Analysis  
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a 
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. 
Probability (P) values of <0.05 were considered to be significant. 
 
Results 
Morphometric Studies  
None of the animals died during the course of the experiment. No significant change in 
body weight (BW) in any group was observed during the experiment. ISO-infusion increased 
heart weight (HW) as well as the HW/body weight (HW/BW) ratios in ISO and UB+ISO groups 
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as compared to sham (p<0.05; Table 2.1) with no significant difference between the two ISO 
groups. UB alone had no effect on HW or HW/BW ratio.  
Table 2.1. Morphometric Measurements 
 SHAM ISO UB+ISO UB  
Parameters (n=6) (n=6) (n=6) (n=6) P value 
BW (g) 30.27±1.00 31.95±0.86 31.60±0.64 31.00±0.76 NS 
HW (mg) 129.7±6.74 167.4±8.98* 178.6±7.46* 144.5±10.8 *<0.01 
HW/BW (mg/g) 4.29±0.21 5.22±0.17* 5.65±0.21* 4.65±0.29 *<0.01 
HW, heart weight; BW, body weight. Values are mean±SEM; *comparison versus SHAM 
group; NS, not significant. 
 
Serum UB Levels  
Measurement of serum UB levels using ELISA demonstrated presence of 16.2±1.3ng/ml 
UB in sham animals. ISO had no effect on serum UB levels. Serum UB levels were increased in 
UB-infused groups when compared to sham or ISO groups (P<0.05; Fig 2.1). However, the 
increase in serum UB levels was higher in UB alone when compared to UB+ISO group.   
 
Figure 2.1. Serum UB Levels. UB infusion increases serum UB levels. *P<0.05 versus sham; 
#
P<0.05 versus ISO; 
$
P<0.05 vs UB+ISO; n=5-6. 
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Echocardiographic Measurements  
M-mode echocardiography showed no significant difference in LVESD, LVEDD, %FS 
and EF% between sham and UB groups. ISO-infusion decreased LVESD in ISO, not in 
UB+ISO, group. LVEDD remained unchanged between the two groups. %FS, EF% and Vcf 
were increased in ISO, not in UB+ISO, group when compared to sham. In fact, %FS, %EF and 
mean Vcf were significantly lower in UB+ISO when compared to ISO group (Table 2.2).  
Table 2.2.  M-mode Echocardiographic Measurements  
 SHAM ISO UB+ISO UB  
Parameters (n=6) (n=6) (n=6) (n=5) P value 
LVESD (mm) 2.73±0.04 2.36±0.06* 2.78±0.06# 2.74±0.16 *<0.05; #<0.05 
LVEDD (mm) 3.90±0.08 3.89±0.02 4.11±0.06 3.97±0.16 NS 
%FS 30.01±0.99 39.26±1.55* 32.50±1.03# 31.31±1.88 *<0.01;#<0.05 
EF% 57.73±1.39 70.07±2.02* 61.14±1.45# 59.51±2.84 *<0.01; #<0.05 
Mean Vcf (circ/sec) 5.99±0.23 10.10±0.62* 6.97±0.28# 6.09±0.39 *<0.001;#<0.001 
Values are mean±SEM; LVESD, LV end-systolic diameter; LVEDD, LV end-diastolic diameter; 
%FS, percent fractional shortening; EF%, percent ejection fraction; Vcf, mean velocity of 
circumferential shortening; *comparison versus SHAM group; 
#
comparison versus ISO group; 
NS, not significant. 
 
Doppler tracings revealed no difference in any parameters between sham and UB groups 
(Table 2.3). ISO-infusion decreased IVRT, IVCT, and ET in both groups when compared to 
sham. However, decrease in these parameters was significantly lower in ISO when compared to 
UB+ISO group (p<0.05; Table 2.3). ISO-infusion increased heart rates in both groups with no 
significant difference between ISO and UB+ISO groups.  
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Table 2.3. Doppler Echocardiographic Measurements 
 SHAM ISO UB+ISO UB  
Parameters (n=6) (n=6) (n=6) (n=5) P value 
IVRT (ms) 12.41±0.01 5.07±0.01* 7.26±0.01*# 12.98±0.01 *<0.05; #<0.01 
IVCT (ms) 11.98±0.01 5.19±0.01* 7.67±0.01*# 13.11±0.01 *<0.01; #<0.001 
ET (ms) 50.22±0.01 39.07±0.01* 46.70±0.01*# 51.47±0.01 *<0.05;#<0.001 
HR (bpm) 428.37±19.36 572.87±23.7* 506.98±17.98* 388.64±18.31 *<0.05 
Values are mean±SEM; IVRT, isovolumetric relaxation time; IVCT, isovolumetric contraction 
time; ET, ejection time ; HR, heart rate ; *comparison versus SHAM group; 
#
comparison versus 
ISO group; NS, not significant.  
 
Fibrosis, Apoptosis and Hypertrophy  
ISO-infusion increased fibrosis in both groups (Fig 2.2A). Quantitative analysis of 
trichrome-stained sections showed that the increase in fibrosis was significantly lower in the 
UB+ISO group when compared to ISO (percent fibrosis, WT-sham, 0.17  0.05; ISO, 1.78  
0.15*; UB+ISO, 1.09  0.16*#; UB, 0.29 ± 0.13; *P<0.01 vs Sham; #P<0.05 vs ISO; n = 5-6; Fig 
2.2B).  
ISO-infusion increased the number of TUNEL-positive myocytes in both groups. 
However, the percentage of apoptotic myocytes was significantly lower in UB+ISO group when 
compared to ISO (percentage of apoptotic myocyte nuclei/total number of nuclei; Sham, 0.07 ± 
0.03; ISO, 0.35 ± 0.07*; UB+ISO, 0.15 ± 0.05
#
; UB, 0.02 ± 0.01; *P<0.01 vs Sham; 
#
P<0.05 vs 
ISO; n = 3-5; Fig 2.2C).  
ISO-infusion increased myocyte cross-sectional area to a similar extent in both groups 
when compared to sham (µm
2
; Sham, 137.5 ± 8.5; ISO, 297.4 ± 9.2*; UB+ISO, 227.3 ± 28.5*; 
UB, 149 ± 4.8; *P<0.01 vs Sham; n = 3-4; Fig 2.2D).  
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Figure 2.2. Myocardial Remodeling 7 Days after ISO-Infusion. A & B) Analysis of fibrosis. 
Panel A exhibits Masson’s trichrome-stained sections 7 days after ISO-infusion. Panel B shows 
quantitative analysis of fibrosis. *P<0.01 versus sham; 
#
P<0.05 versus ISO; n = 5-6. C) 
Quantitative analysis of TUNEL-stained myocytes 7 days after ISO-infusion. *P<0.01 versus 
sham; 
#
P<0.05 versus ISO; n = 3-5. D) Quantitative analysis of myocyte cross-sectional area. 
*P<0.01 versus sham; n = 3-4. 
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Activation of Akt and GSK-3β  
Previously, we have provided evidence that inhibition of PI3-kinase inhibits the 
protective effects of UB in β-AR-stimulated apoptosis in ARVMs (44). PI3-kianse activates Akt 
and activation of Akt plays an anti-apoptotic role (22).  Western blot analysis of LV lysates using 
phospho-specific anti-Akt antibodies showed a significant increase in Akt phosphorylation 
(activity) in both ISO and UB+ISO groups when compared to sham. However, the increase in 
Akt activity was significantly higher in UB+ISO group when compared to ISO (p<0.05; Fig 
2.3A). UB alone had no effect on Akt activity.  
Activation of GSK-3β plays a pro-apoptotic role in β-AR-stimulated apoptosis (30). 
Phosphorylation of an N-terminal serine residue (serine-9) inactivates GSK-3β. Akt is one of the 
upstream kinases involved in phosphorylation (serine-9) and inactivation of GSK-3β (16). 
Western blot analysis of LV lysates using phospho-specific anti-GSK-3β antibodies showed 
decreased phosphorylation (activation) of GSK-3β in ISO, not in UB+ISO, group. GSK-3β 
phosphorylation was significantly higher in UB+ISO when compared to ISO group (WT-sham, 
0.76±0.1; ISO, 0.46±0.04*; UB+ISO, 0.64±0.04
#
; UB, 0.57±0.1; *P<0.05 vs Sham; 
#
P<0.05 vs 
ISO; n = 4-7; Fig 2.3B). UB alone had no effect on GSK-3β phosphorylation.  
 
38 
 
 
Figure 2.3. Activation of Akt and GSK-3β in the Heart. Total LV lysates (70 µg), were analyzed 
by western blot using phospho-specific Akt (serine-473), total Akt, phospho-specific GSK-3β 
(serine-9) and total GSK-3β antibodies.  The lower panels exhibit mean data normalized to total 
Akt or GSK-3β.  A) Phosphorylation (activation) of Akt. *P<0.05 versus sham; #P<0.05 versus 
ISO; n = 6. B) Phosphorylation (inactivation) of GSK-3β. *P<0.05 versus sham; #P<0.01 versus 
ISO; n = 4-7. 
 
Activation of JNKs and ERK1/2  
β-AR-stimulated activation of c-Jun NH2-terminal kinase (JNK) pathway is demonstrated 
to play a pro-apoptotic role in β-AR-stimulated apoptosis (39). Previously, we have provided 
evidence that active GSK-3β may act upstream in the activation of JNKs (44). Western blot 
analysis of LV lysates using phospho-specific anti-JNKs antibodies showed increased 
phosphorylation (activation) of JNKs in ISO, not in UB+ISO, group. Activation of JNKs was 
significantly lower in UB+ISO group when compared to ISO (WT-sham, 0.68±0.16; ISO, 
4.32±0.35; UB+ISO, 1.88±0.59
#
; UB, 0.99±0.43; *P<0.05 vs Sham; 
#
P<0.05 vs ISO; n = 4-7; 
Fig 2.4A). UB alone had no effect on JNKs phosphorylation. ISO in the presence or absence of 
UB had no effect on the activation of ERK1/2 (Fig 2.4B). 
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Figure 2.4. Activation of JNKs and ERK1/2 in the Heart. Total LV lysates (70 µg), were 
analyzed by western blot using phospho-specific JNKs, total JNKs,  phospho-specific ERK1/2 
and total ERK1/2.  The lower panels exhibit mean data normalized to total JNKs or ERK1/2.  A) 
Phosphorylation (activation) of JNKs. *P<0.05 versus sham; 
#
P<0.05 versus ISO; n = 6. B) 
Phosphorylation (activation) of ERK1/2; n = 5. 
 
Expression and Activation of MMP-2 and MMP-9  
MMPs (MMP-2 and MMP-9) play a significant role in  myocardial fibrosis and 
remodeling (46). Western blot analysis of LV lysates demonstrated increased expression (protein 
levels) of MMP-2 in both ISO groups (Fig 2.5A). However, the increase in MMP-2 expression 
was significantly higher in UB+ISO group when compared to ISO. In gel zymography showed 
increased MMP-2 activity in both ISO groups. However, the increase in MMP-2 activity was 
significantly higher in UB+ISO group when compared to ISO (Fig 2.5B). Increased MMP-9 
expression was only observed in UB+ISO group (WT-sham, 0.79±0.1; ISO, 0.73±0.1; UB+ISO, 
1.16±0.1*
#
; UB, 0.66±0.2; *P<0.05 vs Sham; 
#
P<0.05 vs ISO; n = 6; Fig 2.6A). In gel 
zymography failed to show active MMP-9 bands in the LV lysates from these groups (data not 
shown). 
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Figure 2.5. Expression and Activation of MMP-2 in the Heart. Total LV lysates (70µg) were 
analyzed by western blot (using anti-MMP-2 antibodies) or gelatin in-gel zymography. A) 
Expression of MMP-2. GAPDH immunostaining indicates protein loading. *P<0.05 versus 
sham; 
#
P<0.05 versus ISO; n = 6. B) MMP-2 activity. *P<0.01 versus sham; 
#
P<0.05 versus ISO; 
n = 4.  
 
Expression of TIMP-2 and TIMP-4  
Tissue inhibitors of MMPs (TIMPs) play an important role in regulation of MMPs 
activity (32; 51). Western blot analysis of LV lysates demonstrated that ISO alone has no effect 
on TIMP-2 protein levels. However, UB alone or in the presence of ISO significantly increased 
TIMP-2 protein levels (Fig 2.6B). ISO in the presence or absence of UB had no effect on protein 
levels of TIMP-4. UB alone increased TIMP-4 protein levels when compared to ISO or UB+ISO 
groups (data not shown). 
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Figure 2.6. Expression of MMP-9 and TIMP-2 in the Heart.  Total LV lysates (70µg) were 
analyzed by western blot using anti-MMP-9 or anti-TIMP-2 antibodies. GAPDH 
immunostaining indicates protein loading. A) Expression of MMP-9. *P<0.05 versus sham; 
#
P<0.05 versus ISO; n = 6. B) Expression of TIMP-2. *P<0.01 versus sham; 
#
P<0.05 versus ISO; 
n = 4. 
 
UB Modulates Expression of MMPs and TIMP-2 in Cardiac Fibroblasts 
 ISO treatment increased MMP-2 expression in adult cardiac fibroblasts as analyzed by 
western blots. However, the increase in MMP-2 expression was significantly higher in UB+ISO 
group when compared to ISO (Fig 2.7A). In-gel zymography showed a trend towards increased 
MMP-2 activity in response to ISO. However, MMP-2 activity was significantly higher in 
UB+ISO group as compared to control and ISO-treated samples (Fig 2.7B). These effects of UB 
on MMP-2 expression were negated by pretreatment with a neutralizing anti-UB antibodies (Fig 
2.7C). Treatment with rUB also enhanced ISO-mediated increases in MMP-2 expression (Fig 
2.7D). However, the effects were observed at a higher concentration (100 µg/ml). MMP-9 
expression tended to be higher in UB+ISO group when compared to sham (P=0.06; n=6; Fig 
2.8A). ISO treatment had no effect on TIMP-2 protein levels. However, TIMP-2 protein levels 
were significantly higher in UB+ISO samples when compared to control or ISO-treated samples 
(Fig 2.8B).  
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Figure 2.7. Expression and Activity of MMP-2 in Cardiac Fibroblasts. A & B) Cardiac 
fibroblasts were pretreated with UB (10 µg/ml) for 30 min followed by treatment with ISO (10 
µM) for 48 h. A) Cell lysates (20 µg) were analyzed by western using anti-MMP-2 antibodies. 
*P<0.05 versus control (CTL); 
#
P<0.05 versus ISO; n = 11. B) Concentrated conditioned media 
(2 µg) were analyzed by gelatin in-gel zymography. *<0.01 versus CTL; 
#
P<0.05 versus ISO; n 
= 3. C) Cells were pretreated with neutralizing anti-UB antibody (Ab) for 30 min followed by 
treatment with UB for 30 min. The cells were then treated with ISO for 48 h. Cell lysates (20 µg) 
were analyzed by western using anti-MMP-2 antibodies. *P<0.05 versus CTL; 
$
P<0.05 versus 
UB+ISO; n=3. D) Cells were pretreated with rUB (10 or 100 µg/ml) for 30 min followed by 
treatment with ISO for 48 h. Cell lysates (20 µg) were analyzed by western using anti-MMP-2 
antibodies. *P<0.05 versus CTL; 
#
P<0.05 versus ISO; n=3. Actin immunostaining indicates 
protein loading.   
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Figure 2.8. Expression of MMP-9 and TIMP-2. Cardiac fibroblast were pretreated with UB (10 
µg/ml) for 30 min followed by treatment with ISO (10 µM) for 48 h. Cell lysates (20 µg) were 
analyzed by western blot using anti-MMP-9 or anti-TIMP-2 antibodies. Actin immunostaining 
indicates protein loading. A) Expression of MMP-9. 
#
P=0.06 versus ISO; n = 6. B) Expression of 
TIMP-2. *P<0.05 versus CTL; #P<0.05 versus ISO; n = 3-4. 
 
UB Activates Akt, and Inhibition of Akt Inhibits MMP-2 Expression in Cardiac Fibroblast  
To investigate if UB alone or in combination with ISO activates Akt, cardiac fibroblasts 
were pretreated with UB followed by treatment with ISO for 15 min. Analysis of cell lysates 
using phospho-specific antibodies showed that UB or ISO alone had no effect on Akt activation. 
However, UB in the presence of ISO significantly increased Akt activity as compared to control 
or ISO-treated samples (Fig 2.9A). MMP-2 activation is shown to be dependent on activation of 
Akt in the heart (45). Inhibition of Akt using MK-2206 (18; 37) significantly inhibited UB+ISO-
mediated increases in MMP-2 expression (fold change vs CTL; UB+ISO, 1.71±0.1*; 
MK+UB+ISO, 1.23±0.2
#
; MK, 0.59±0.3*; *P<0.05 vs Sham; 
#
P<0.05 vs UB+ISO; n = 5; Fig 
2.9B).   
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Figure 2.9. Activation of Akt and its Role in MMP-2 Expression. Cardiac fibroblast were 
pretreated with UB (10 µg/ml) for 30 min followed by treatment with ISO (10 µM) for 15 min to 
measure Akt activation (A). To measure MMP-2 expression, cardiac fibroblasts were pretreated  
with MK-2206 (MK; 1 μM) for 30 min, then with UB (10 µg/ml) for 30 min followed by 
treatment with ISO (10 μM) for 48 h (B).  Cell lysates (20 µg), were analyzed by western blot 
using phospho-specific anti-Akt (serine-473) or anti-MMP-2 antibodies. The lower panels 
exhibit mean data normalized to total Akt or actin. A) Phosphorylation (activation) of Akt. 
*P<0.05 versus CTL; #P<0.05 versus ISO; n = 5. B) Expression of MMP-2. *P<0.05 versus 
CTL; #P<0.05 versus UB+ISO; n = 5. 
 
Discussion 
Previously, we have provided evidence that β-AR stimulation increases levels of 
extracellular UB and treatment with UB plays a protective role in β-AR-stimulated apoptosis in 
ARVMs (44). This is the first study investigating the role of exogenous UB in the heart, 
specifically in response to chronic β-AR stimulation. Here we confirm our previous finding of an 
anti-apoptotic function for UB in vivo, and show that UB plays an important role in β-AR-
stimulated myocardial remodeling with effects on left ventricular function, fibrosis, and myocyte 
apoptosis. UB infusion enhanced serum UB levels. Exogenous UB depressed β-AR-stimulated 
increases in systolic and diastolic functional parameters of the heart. Increase in cardiac myocyte 
apoptosis and myocardial fibrosis was significantly lower in the presence of exogenous UB. 
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Exogenous UB enhanced activation of anti-apoptotic kinase Akt, while decreasing the activation 
of pro-apoptotic kinases, GSK-3β and JNKs. It increased protein levels of MMP-2, MMP-9 and 
TIMP-2 in the presence of ISO. In isolated cardiac fibroblast, UB enhanced expression of MMP-
2 and TIMP-2. It activated Akt and inhibition of Akt decreased MMP-2 expression. 
Sympathetic nerve activity increases in the heart during cardiac failure. Prolonged 
stimulation of the β-adrenergic neurohormonal axis contributes to the progression of heart failure 
and mortality in animal models and human patients (3; 13). Catecholamines, released during 
heightened adrenergic drive, accumulate in the interstitial space of the heart (6; 8). This 
accumulation of catecholamines may contribute to left ventricular dysfunction (10). UB is a 
normal constituent of plasma or serum (11; 29; 47). Levels of UB increase in plasma or serum of 
patients under a variety of pathological conditions (26). However, the role of plasma UB in the 
heart has not yet been investigated. Previously, we have shown that β-AR stimulation increases 
extracellular levels of UB in ARVMs (44). Here we observed basal presence of UB in the serum 
of ICR mice. Infusion of UB enhanced serum UB levels in the presence or absence of β-AR 
stimulation. It was interesting to note that serum UB levels were lower in the presence of β-AR 
stimulation, and β-AR stimulation alone had no effect on serum UB levels. These observations 
suggest the possibility that β-AR stimulation may enhance UB absorption in vivo. Isoproterenol 
is shown to increase cardiac output without affecting renal blood flow in dog, human, and lamb 
(5; 40). However, the possibility of increased renal blood flow and renal clearance of UB in the 
presence of isoproterenol cannot be ruled out. A significant finding of this study is that 
exogenous UB has the potential to play an important role in the remodeling process of the heart 
by affecting β-AR-stimulated increases in myocyte apoptosis and myocardial fibrosis.  
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  Ventricular hypertrophy is considered as an important compensatory mechanism that 
allows the heart to maintain its output. Chronic β-AR-stimulation is shown to induce 
hypertrophy, and increase heart rate and LV systolic function (20; 49; 50). Indicators of 
hypertrophy such as HW/BW ratio, and myocyte cross-sectional area were increased to a similar 
extent in both ISO-groups. Interesting finding of this study is that exogenous UB in the presence 
of ISO restored systolic function to normal levels as indicated by decreased %FS, %EF and Vcf. 
It partially restored ISO-mediated decrease in IVRT, IVCT, and ET. Changes in heart rate are 
suggested to affect echocardiographic parameters in mice (52). As observed previously (23), 
ISO-infusion increased heart rate in ICR mice. UB alone or in the presence of ISO had no effect 
on basal or ISO-mediated increases in heart rates. Therefore, the observed changes in 
echocardiographic parameters between ISO and UB+ISO groups may not be due to the changes 
in heart rate. Extracellular UB is shown to promote intracellular Ca
++
 flux and reduce cAMP 
levels through a G protein-coupled receptor in THP1 cells (41). Therefore, UB may affect 
systolic and diastolic parameters of the heart by modulating levels of intracellular Ca
++
 and/or 
cAMP. However, further investigations are needed to understand the mechanism by which 
exogenous UB modulates heart function in the presence of β-AR agonist. 
Cardiac myocyte apoptosis plays a crucial role in the pathogenesis of heart failure (17; 
21; 33). β-AR-stimulated activation of JNKs and GSK-3β plays a pro-apoptotic role via the 
involvement of mitochondrial death pathway (30; 39). Previously, UB is shown to activate PI3-
kinase and inhibit β-AR-stimulated activation of JNKs and GSK-3β, and mitochondrial death 
pathway of apoptosis (44). PI3-kinase is an upstream activator of Akt (35), while Akt acts upstream 
in the inactivation of GSK-3β (16). Active GSK-3β may act upstream in the activation of JNKs 
(44). Here we show exogenous UB enhances β-AR stimulated activation of Akt, while inhibiting 
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activation of GSK-3β and JNKs. These in vivo data confirm our previous in vitro findings, and 
suggest that activation of PI3-Kinase/Akt pathway may be a mechanism involved in anti-apoptotic 
effects of exogenous UB.  
 Chronic sympathetic stimulation is shown to induce growth of interstitial tissue in the 
heart leading to fibrosis (7). MMPs and TIMPs play an important role in the remodeling of 
extracellular matrix (46). Previously, we have shown that chronic β-AR stimulation increases 
myocardial fibrosis (23). Consistent with these observations, we observed increased fibrosis 
following chronic β-AR stimulation in ICR mice. The new finding of this study is that 
exogenous UB inhibits chronic β-AR-stimulated increases in myocardial fibrosis. It enhanced 
chronic β-AR-stimulated increases in the expression and activity of MMP-2. It also increased 
expression of MMP-9 and TIMP-2 in the heart. Use of isolated adult cardiac fibroblasts 
confirmed our in vivo findings with respect to the expression of MMPs and TIMP-2 in response 
to UB. Of note, a higher concentration of rUB (as compared to bovine UB) was required to 
observe increased expression of MMP-2 in the presence of isoproterenol in fibroblasts (Fig 
2.7D). The reasons may include differential modification of UB from different sources. UB is 
shown to be modified by acetylation of lysines, oxidation of methionine, and nitration of tyrosine 
(25; 54). These modifications may influence interaction of extracellular UB with its receptor 
and/or other proteins. The concentration of TIMP-2 is suggested to determine the role of TIMP-2 
in activation of MMP-2. At low concentrations, TIMP-2 may activate MMP-2 on the cell surface 
with the MT1-MMP-TIMP-2 complex serving as a receptor for proMMP-2, whereas at higher 
concentrations, TIMP-2 may neutralize MT1-MMP and prevent activation of MMP-2 (24). The 
data presented here suggest that exogenous UB decreases chronic β-AR-stimulated myocardial 
fibrosis by modulating expression of MMPs and TIMP-2. Previously, we have reported that 
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chronic β-AR stimulation increases MMP-9 expression in the heart (23). Here we did not 
observe increased expression of MMP-9 in response to chronic β-AR stimulation. The observed 
discrepant findings may relate to the use of different mouse strains. Previous study used 
129xblack Swiss mice, while the current study uses ICR mice.   
Increased MMP-2 expression is suggested to be dependent on Akt activation in the rat 
heart during ischemia/reperfusion (45). In the current study, UB enhanced Akt activation in the 
heart and in isolated cardiac fibroblasts in the presence of β-AR stimulation. Inhibition of Akt 
decreased UB+ISO-mediated increases in MMP-2 expression. These data suggest a potential 
relationship between Akt activation in response to UB treatment and MMP-2 expression in the 
heart.  
 
Perspective 
The data presented here are novel and of significant interest since exogenous UB 
modulates β-AR-stimulated myocardial function, and inhibits myocardial fibrosis and cardiac 
myocyte apoptosis. The structural changes related to cardiac myocyte apoptosis and extracellular 
matrix play a significant role in modulation of myocardial function and in the progression to 
heart failure. Therefore, elucidation of processes that can shift the balance from myocyte 
apoptosis to survival may have clinical implications. In addition, analysis of components of 
extracellular matrix, including collagen type I and IV, laminin, fibronectin etc, may provide 
insight into the modulation of heart function in the presence of exogenous UB. It should be 
emphasized that our data on heart function and signaling are obtained seven days after ISO-
infusion. The experimental time-point should be extended beyond seven days to investigate long-
term effects of exogenous UB.  
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Abstract 
Stimulation of β-adrenergic receptor (β-AR) increases extracellular levels of ubiquitin (UB), and 
exogenous UB plays an important role in β-AR-stimulated myocardial remodeling with effects 
on LV function, fibrosis and myocyte apoptosis. Cardiac fibroblasts play a critical role in 
maintaining the normal function of the heart, and in the reparative and fibrosis processes during 
pathological cardiac remodeling. This study investigated the role of extracellular UB on cardiac 
fibroblast function and phenotype, and involvement of CXCR-4 receptor (a potential receptor for 
extracellular UB) in UB-mediated modulation of fibroblast function and phenotype. Using 
primary cultures of adult rat cardiac fibroblasts, we provide evidence that extracellular UB 
interacts with the cell surface. Extracellular UB induced rearrangement of fibrillar actin into the 
formation of stress fibers as analyzed by phalloidin-FITC and α-smooth muscle actin (α-SMA, a 
marker for transdifferentiation of fibroblasts into myofibroblasts) staining. However, it inhibited 
the formation of lamellopodia and filopodia. Western blot analysis revealed increased expression 
of α-SMA in response to extracellular UB. Extracellular UB co-immunoprecipitated with 
CXCR-4 receptor. Proximity ligation assay confirmed interaction of extracellular UB with 
CXCR-4. Extracellular UB inhibited the migration of cells into the wound. It activated ERK1/2, 
while it had no effect on the activation of Akt. It increased the expression of vascular endothelial 
growth factor A (VEGF-A), while decreasing the expression of β3 integrins. Most of the effects 
of extracellular UB were negated by pretreatment with AMD-3100. Two UB mutants (mUB V70 
and mUB F4), unable to interact with CXCR-4, had no effect on the expression of VEGF-A and 
β3 integrins. Thus, extracellular UB, at least in part acting via the CXCR-4 receptor, plays an 
important role in modulation of fibroblast function and phenotype.           
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Introduction 
 Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells. 
The most important intracellular function of UB is to regulate protein turnover by the ubiquitin-
proteasome pathway (16). The ubiquitin-proteasome pathway may regulate receptor 
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in 
cardiac myocytes (56). UB is a normal constituent of plasma. Elevated levels of UB are 
described in the serum or plasma of patients with parasitic and allergic diseases (3), alcoholic 
liver disease (47), type 2 diabetes (1), β2-Microglobulin amyloidosis (35) and chronic 
hemodialysis patients (2). Patients with traumatic brain injury are shown to have increased UB 
levels in the cerebrospinal fluid (27). Extracellular UB is proposed to have pleiotropic functions 
including regulation of immune response, anti-inflammatory and neuroprotective activities (26; 
28; 36), as well as regulation of growth and apoptosis in hematopoetic cells (10). Previously our 
lab has shown that β-adrenergic receptor (β-AR) stimulation increases extracellular levels of UB, 
and treatment of adult rat ventricular myocytes with UB inhibits β-AR-stimulated apoptosis (41). 
In vivo, exogenous UB decreased β-AR-stimulated increases in cardiac myocyte apoptosis and 
myocardial fibrosis (11).  
 The G protein–coupled receptor CXC chemokine receptor (CXCR)-4 is abundantly 
expressed in immune cells and tissues, including cardiac fibroblast (21). CXCR-4 plays an 
important role in a variety of biological processes, and is suggested to be involved in the 
pathophysiology of various disease processes, such as cancer, HIV, ischemic myocardial injury, 
and angiogenesis (49). Stromal derived factor-1α (SDF-1α) is the cognate ligand for CXCR-4 
which is implicated in homing of hematopoietic stem cells during wound repair (7). SDF-1α is 
shown to have cardioprotective effects against ischemia/reperfusion injury by promoting anti-
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apoptotic program (21). Interestingly, CXCR-4 has been identified as a receptor for UB in THP1 
leukemia cell line (38). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini et al., 
provide evidence that the ubiquitin-CXCR-4 interaction follows a two-site binding mechanism in 
which the hydrophobic surfaces surrounding Phe-4 and Val-70 are important for receptor 
binding, whereas the flexible C terminus facilitates receptor activation (39). Recently, we 
provided evidence that extracellular UB, acting via CXCR-4 receptor, increases expression of 
angiogenic molecules and stimulates angiogenesis in cardiac microvascular endothelial cells 
(45).  
 Cardiac fibroblast play a critical role in maintaining the normal function of the heart, and in 
the remodeling process of the heart that occurs in response to myocardial infarction, 
hypertension and heart failure (42). The objective of this study was to investigate the role of 
extracellular UB on cardiac fibroblast phenotype and function, and to define the role of CXCR-4 
receptor in modulation of fibroblast phenotype and function in response to extracellular UB. The 
data presented here suggest that extracellular UB interacts with fibroblasts and CXCR-4 
receptor, induces cytoskeletal reorganization, induces intracellular signaling, and inhibits 
migration of cells into the wound. Most of these effects of UB are inhibited by CXCR-4 receptor 
antagonist. The data presented here also suggest that extracellular UB and SDF-1α may elicit 
different signaling mechanisms.  
 
Materials and Methods 
Vertebrate Animals  
All experiments and procedures were reviewed and approved by the East Tennessee State 
University Institutional Committee on Animal Care and conform to the Guide for the Care and 
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Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). Male Sprague-Dawley rats (average wt: 200-225g; Harlan, 
Indianapolis, IN) were used for isolation of resident cardiac fibroblast cells. Rats were 
anesthetized using a mixture of isoflurane (2.5%) and oxygen (0.5 l/min), and the heart was 
excised following a bilateral cut in the diaphragm. Animals were euthanized by exsanguinations. 
 
Fibroblast Isolation and Treatment  
Adult rat cardiac fibroblasts were isolated as described (54). The cells were grown to 
confluence and serum-starved for 48 h before use. Experiments were performed using first and 
second passage cells. The cells were pretreated with AMD 3100 (10 µM; Sigma) or PD98059 
(15μM; Calbiochem) for 30 min followed by treatment with UB (10 µg/ml; Sigma), biotin-UB 
(500 ng/ml; Boston Biochem), mutated UB (mUB V70 and mUB F4; 10μg/ml; Boston Biochem) 
or SDF-1α (1nM; Peprotech) for indicated time points. To investigate cellular interaction of UB, 
cells were treated with FITC-UB (500 ng/ml; Boston Biochem) for 30 min. 
 
Immunocytochemical Analysis  
Immunocytochemical analysis was carried out as described (31). Briefly, isolated cardiac 
fibroblast were plated on coverslips, fixed in 3.7% formaldehyde and permeabilized using 0.2% 
Triton X-100. Coverslips were incubated in anti-α-SMA (1:500; Sigma) antibodies in 1% BSA 
followed by Alexa Fluor-conjugated (1:500; Invitrogen) secondary antibodies. The coverslips 
were then counterstained with Hoechst 33258, mounted and visualized using a fluorescent 
microscope.   
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Actin Polymerization Assay  
Serum starved confluent cultures of cardiac fibroblast were treated with UB for 24 h. 
Cells were washed twice with PBS, fixed in 3.7% formaldehyde solution, and permeabilized 
with 0.2% Triton X-100. Nonspecific binding was blocked by incubating slides for 20 min at 
room temperature in blocking solution (1% BSA in PBS). Cells were stained with Phalloidin-
FITC (1U/slide in blocking solution; Sigma-Aldrich, St. Louis, MO) for 20 min at room 
temperature in the dark. After washing, the slides were mounted with SlowFade (Invitrogen 
Corp., Carlsbad, CA) and visualized under fluorescent microscope using a rhodamine filter. 
Images were acquired using a Nikon TE-2000 microscope with a Retiga-1300 color cooled 
camera.  
 
Co-immunoprecipitation Assay  
Total cell lysates (300 µg proteins) were incubated overnight at 4°C with 3 µg of anti-
CXCR-4 (Abcam) antibody in 500 µl of TNT buffer (20 mM Tris·HCl, pH 7.5, 137 mM NaCl, 
20 mM NaF, 5 mM EDTA, 1 mM PMSF, 10 mM sodium pyrophosphate, 0.2 M sodium 
orthovanadate, 8 µg/ml aprotinin and 2 μg/ ml leupeptin, digitonin 0.05%, and 1% Triton X-
100). Protein A/G beads (60 µl, Thermo Scientific, Rockford, IL) were added to the mixture and 
incubated for an additional hour with rocking. The immunocomplexes were then washed six 
times with cold PBS. The immunoprecipitated proteins were resolved by SDS-PAGE and 
transferred to PVDF membranes. The membranes were then probed with anti-UB (Santa Cruz) 
antibody as described for western blot analyses. 
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DuoLink In Situ Proximity Ligation Assay  
To detect the interaction between CXCR-4 and UB, in situ proximity ligation assay 
(PLA) was performed using Duolink kit according to the manufacturer's protocol (Olink 
Bioscience, Uppsala, Sweden). After fixing and permeabilization, the cells were incubated 
overnight with anti-UB antibodies (monoclonal; Santa Cruz) and anti-CXCR-4 antibodies 
(polyclonal; Abcam). The cells were washed with PBS and incubated with appropriate secondary 
antibodies. After a ligation reaction at 37°C of the DNA chains directly coupled to the PLA 
probes, the cells were mounted and detection of the amplified probe was performed using 
fluorescent microscope. 
 
Migration Assay  
Movement of cells through a wound introduced in a cell monolayer was determined as 
described (19). Briefly, cardiac fibroblasts were grown as a confluent monolayer. After cells 
were made quiescent in serum free medium for 48 h, a wound was created in the center of the 
cell monolayer by gentle removal of attached cells using a sterile plastic pipette tip. Cell debris 
was removed by a PBS wash and images of the wound were acquired using a Nikon TE-2000 
microscope with a Retiga-1300 color cooled camera. The cells were then incubated in serum-free 
DMEM containing UB for 24 and 48 h. Images were again acquired using as described above. 
The wound area was measured using Bioquant Image Analysis software (Bioquant Image 
Analysis Corp., Nashville, TN). The ability of cells to migrate into the wound area was assessed 
by comparing micrographs at time zero, 24 and 48 h along the wounded area. The percentage of 
wound area recovered was calculated by dividing the wound area after 24 h or 48 h by the initial 
wound area at time zero, multiplied by 100. 
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Western Blot Analysis 
Cell lysates were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1 mM EGTA, 1 mM EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X-
100, and 1 mM PMSF]. Equal amounts of total proteins (20 µg from cell lysates) were resolved 
on 10% SDS-polyacrylamide gels. The proteins were transferred onto PVDF membrane. The 
blots were then probed with primary antibodies directed against p-Akt (1:1000; Cell Signaling 
Tech.), p-ERK1/2 (1:2000; Cell Signaling Tech.), β3-integrin (1:1000; Santa Cruz), VEGF-A 
(1:200; Santa Cruz), or α-SMA (1:20000; Sigma) and appropriate secondary antibodies. 
Membranes were then stripped and probed with Akt, ERK1/2, actin (Chemicon) or GAPDH 
(Santa Cruz) antibodies to normalize protein loading. Band intensities were quantified using 
Kodak photo documentation system (Eastman Kodak Co.). To detect biotin-labelled UB, the 
membranes were incubated overnight in extra-avidin peroxidase (Sigma; 1:2000 dilution in 
TBST). The biotin-labelled UB was visualized using chemiluminescence reagents.  
 
Statistical Analysis  
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a 
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. 
Probability (P) values of <0.05 were considered to be significant. 
 
Results 
Extracellular UB Interacts with Fibroblasts and Induces Cytoskeletal Reorganization  
To investigate if extracellular UB interacts with cells, cells were treated with FITC-UB 
for 30 min.  As a negative control, cells were incubated with FITC-labeled secondary antibodies 
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(1:500) for 30 min. Visualization of cells using fluorescent microscope showed clear staining of 
cells with FITC-UB. No staining was observed in control cells or cells incubated with FITC-
labeled secondary antibodies (Fig 3.1).  
 
Figure 3.1. Cellular Interaction of Extracellular UB. Cardiac fibroblasts were incubated with 
FITC-UB (500 ng/ml) or FITC-labelled secondary antibodies (CTL-FITC) for 30 min. The cells 
were visualized by fluorescent microscope and photographed. CTL, control.    
 
The rearrangement of actin in fibroblast is one of the driving forces of migration into the 
wound (23; 53). In anchorage dependent cells, like fibroblast, there are two distinct cytoskeletal 
arrangements: the geodom (polygonal net) and stress fibers (13). To analyze the actin 
cytoskeleton, fibroblasts were treated with UB for 24 h followed by Phalloidin-FITC staining. 
This analysis showed the presence of geodoms in untreated cells (Fig 3.2A). UB treated cells 
mostly showed absence of geodoms. UB treatment enhanced polymerization of actin into stress 
fibers (yellow arrows). However, there was no presence of filamentous membrane projections 
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called filopodia or lamellipodia in the UB-treated cells (Fig 3.2B). Similar observations were 
made when fibroblasts were immunostained for α-smooth muscle actin (α-SMA; Fig 3.2 C&D). 
Western blot analysis of cell lysates using anti-α-SMA antibodies showed increased expression 
of α-SMA 48 h after UB treatment (Fig 3.2E).   
 
Figure 3.2. Extracellular UB Induces Cytoskeleton Rearrangement, and Increases Expression of 
α-Smooth Muscle Actin (α-SMA): A-D. Semi-confluent cultures of cardiac fibroblast were 
treated with UB for 24 h. The cells were stained with Phalloidin-FITC or anti-α-smooth muscle 
actin (α-SMA) antibodies and visualized using fluorescent microscope (20 or 40X). Panels A & 
B depict representative images from CTL and UB-treated cells following Phalloidin-FITC 
staining. The yellow arrows indicate bundles of actin filaments called stress fibers that are 
required for the traction of the rear of the cells toward the leading edge during migration (B). 
Panels C & D depict representative images from CTL and UB-treated cells following 
immunocytochemical staining using anti-α-SMA antibodies. E. Western blot analysis of α-SMA. 
Cells were treated with UB for 48 h.  Cell lysates were analyzed by western using anti-α-SMA 
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antibodies. The lower panel exhibits the mean data normalized with GAPDH. *P<0.05 vs control 
(CTL); n=5. 
 
 
UB Interacts with CXCR-4 Receptors  
CXCR-4 is identified as a receptor for extracellular UB in THP-1 cells (38). Co-
immunoprecipitation is considered a standard method to determine if two proteins of interest 
form a complex. To investigate the interaction of UB with CXCR-4 receptor, fibroblasts were 
treated with Biotin-UB for 30 min. Cell lysates were immunoprecipitated with anti-CXCR-4 
antibody. The resultant immunoprecipitates were analyzed by western blots using extra-avidin 
peroxidase to detect Biotin-UB. This analysis showed the presence of Biotin-UB in cell lysates 
immunoprecipitated with anti-CXCR-4 antibodies (Fig 3.3A). Binding specificity of UB with 
CXCR-4 receptor was next analyzed by pretreatment of cells with AMD-3100 (CXCR-4 
antagonist) or SDF-1α (a known ligand for CXCR-4 receptor) for 30 min followed by treatment 
of cells with Biotin-UB for different time points (15 min, 3 h and 24 h). Western blot analysis of 
cell lysates using extra-avidin peroxidase showed that pretreatment with AMD-3100 almost 
completely inhibits binding of Biotin-UB to the cells at all different time-points. SDF-1α also 
decreased binding of Biotin-UB at all different time points. However, this inhibition was more 
pronounced at 3 and 24 h (Fig 3.3B). Pretreatment with AMD3100 also inhibited binding of 
FITC-UB to the cells (Fig 3.3C). To confirm interaction of UB with CXCR-4, we used a recently 
developed commercial assay (Duolink) called proximity ligation assay (PLA). The PLA 
identifies interactions between two proteins in their native form. This assay results in a 
fluorescent signal in the form of a spot when the two proteins of interest are closer than 40nm. 
The specificity of the assay was tested using single antibodies directed against UB and CXCR-4. 
This assay showed a few positive spots for interaction of UB with CXCR-4 receptor in untreated 
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cells. This may be due to the fact that endogenous UB can bind to CXCR-4 receptors on the 
cytoplasmic side of the transmembrane protein (29). However, clear increase in the positive 
signal for the interaction of UB with CXCR-4 was observed in cells treated with UB as indicated 
by an increase in bright red fluorescent spots when compared to CTL (Fig 3.3D). 
 
Figure 3.3. Interaction of UB with CXCR-4 Receptor: A. Fibroblast were treated with biotin-
labeled UB (b-UB; 10 μg/ml) for 30 min. Cell lysates were immunoprecipitated with anti-
CXCR-4 antibodies. Immunoprecipitates were analyzed by western blot using extra-avidin 
peroxidase. Unlabeled UB and b-UB served as negative and positive controls, respectively. B. 
Cells were pretreated with AMD 3100 (AMD; 10 μm) or SDF-1α (SDF; 1 nM) for 30 min  
followed by treatment with b-UB for 15 min, 3 h or 24 h. Cell lysates were analyzed by western 
blot using extra-avidin peroxidase. C. Cells were pretreated with AMD  for 30 min followed by 
treatment with FITC-UB for 30 min. Cells were visualized using fluorescent microscope. D. 
Fibroblast were treated with UB for 24 h. The cells were then used for PLA using anti-UB and 
anti-CXCR-4 antibodies. Increased fluorescent red staining in UB-treated sample indicates 
interaction of UB and CXCR-4. 
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Extracellular UB Inhibits Migration of Fibroblast into the Wound 
Fibroblasts play a key role in the normal healing process after injury (30). They migrate 
into the wound site and proliferate, and play a significant role in the reconstitution and deposition 
of fibrotic scar (14). They also play a significant role in the repair processes of the heart 
following myocardial infarction (43; 55). To examine the functional effects of extracellular UB 
on fibroblast cell migration, we used an in vitro migration (scratch) assay as previously described 
(19). Migratory potential of fibroblasts into the wound was clearly present in the untreated cells 
as observed by the decrease in the percent wound area recovered following 24 and 48 h after 
incubation (Fig 3.4A). Interestingly, UB treatment significantly inhibited the percent wound area 
recovered at both time points (24 h; CTL, 45 % vs UB, 14 %; 48 h; CTL, 64 % vs UB, 35 %; 
n=5; Fig 3.3B&C). Pretreatment with AMD3100 significantly enhanced the migration of cells 
into the wound at both time points (CTL, 45±3; UB, 14±4*; AMD+UB, 34±6
$
; AMD, 47±3; 24 
h; CTL, 64±2; UB, 35±6*; AMD+UB, 59±5
$
; AMD, 63±5; 48 h; *P<0.05 vs CTL; 
$
P<0.05 vs 
UB; n=5; Fig 3.4B&C). AMD 3100 alone had no effect on the migration of cells into the wound. 
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Figure 3.4. Extracellular UB Inhibits Migration of Cardiac Fibroblast: Confluent fibroblast 
monolayers were wounded using a sterile pipette tip and pretreated with AMD followed by 
treatment with UB for 24 or 48 h. The ability of cells to migrate into the wound was assessed 
following 24 or 48 h after UB treatment. Panel A demonstrates the wound area at 0 and 48 h 
after treatment. Wound healing was assessed by calculating percent of recovered wound area. 
Panel B and C represents the mean data of percent wound area recovered 24 and 48 h after UB 
treatment; *P<0.05 versus CTL; 
$
P<0.05 versus UB; n = 5.   
 
Activation of Intracellular Signals by Extracellular UB, and Involvement of CXCR-4 Receptor  
A variety of growth factors activate ERK1/2 (52). UB treatment is also shown to activate 
ERK1/2 in THP-1 cells (40). To analyze the activation ERK1/2 in cardiac fibroblasts and 
involvement of CXCR-4 receptors, cells were treated with AMD3100 or PD98059 (a selective 
inhibitor of ERK1/2 pathway) followed by treatment with UB for 15 min. Western blot analysis 
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of cell lysates using phospho-specific anti-ERK1/2 antibodies showed increased phosphorylation 
(activation) of ERK1/2 in response to UB. Pretreatment with PD98059 completely inhibited 
activation of ERK1/2, while inhibition of ERK1/2 was only partial in the presence of AMD3100 
(CTL, 1±0.01; UB, 4.73±0.8*; AMD+UB, 2.4±0.8*
$
; PD+UB
$
, 0.05±0.02; AMD, 0.93±0.38; 
*P<0.05 vs CTL; 
$
P<0.05 vs UB; n = 5; Fig 3.5A). Similar observations were made when cells 
were treated with SDF-1α in the presence of AMD3100 or PD98059 (CTL, 1±0.01; SDF, 
3.95±0.94*; AMD+SDF, 2.52±0.62*
$
; PD+SDF, 0.74±0.68
$
; AMD, 0.93±0.38; *P<0.05 vs 
CTL; 
$
P<0.05 vs SDF; n = 5; Fig 3.5B). AMD 3100 alone had no effect on the activation of 
ERK1/2.  
Previously, we have provided evidence that inhibition of PI3-kinase inhibits the 
protective effects of UB in β-AR-stimulated apoptosis in ARVMs (41). PI3-kinase acts upstream 
in the activation of Akt, and activation of Akt is generally considered as an anti-apoptotic signal 
(22).  Western blot analysis of cell lysates using phospho-specific anti-Akt antibodies showed no 
significant increase in Akt phosphorylation in response to UB treatment. On the other hand, 
SDF-1α increased Akt phosphorylation within 15 min. Pretreatment with AMD3100 inhibited 
SDF-1α-mediated activation of Akt (CTL, 1.00±0.01; UB, 1.24±0.19; AMD+UB, 1.36±0.33; 
SDF, 1.74±0.23*; AMD+SDF, 0.81±0.26
$
; AMD, 1.25±0.24; *P<0.05 vs CTL; 
$
P<0.05 vs SDF; 
n = 5, Fig 3.5C).  
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Figure 3.5. UB Activates ERK1/2, not Akt: Serum starved confluent cultures of fibroblasts were 
pretreated with AMD, or PD98059 (PD; 15 μM) for 30 min followed by treatment with UB or 
SDF-1a (SDF) for 15 min. Cell lysates were analyzed by western blot using phospho-specific 
ERK1/2 or   Akt (serine-473) antibodies. The lower panels exhibit mean data normalized to total 
ERK1/2 or Akt. Both UB and SDF increased activation of ERK1/2; *P<0.05 versus CTL, 
$
P<0.05 versus UB, n = 6 (A); *P<0.05 versus CTL;
 #
P<0.01 versus SDF, n = 4-7 (B); *P<0.05 
versus CTL, 
$
P<0.05 versus SDF, n = 4-6 (C). 
 
Extracellular UB Affects Expression of β3-intergrin and VEGF-A  
Integrins provide linkages between ECM proteins and the actin cytoskeleton, thereby 
providing adhesion of cells to the substratum and playing a crucial role in cell migration (20; 50). 
Cardiac fibroblasts predominantly express β3 integrins (5).  Western blot analysis of cell lysates 
using anti-β3-integrin antibodies showed a significant decrease in the  expression of β3 integrin 
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in UB-treated (24 h) cells compared to CTL (Fig 3.6A). AMD3100 alone had no significant 
effect on β3 integrin expression. However, pretreatment with AMD3100 almost completely 
inhibited UB-mediated decrease in the expression of β3 integrin (CTL, 1.00±0.01; UB, 
0.45±0.09*; AMD+UB, 0.99±0.22; AMD, 0.97±0.18; *P<0.05 vs CTL; n = 5; Fig 3.6A). The 
UB-CXCR-4 interaction is suggested to involve the hydrophobic surfaces surrounding UB 
residues Phe-4 and Val-70 (39). To further investigate the role CXCR-4 in β3 integrin 
expression, cells were treated with two different mutated UBs; F4A and V70A. Western blot 
analyses of cell lysates showed that these two mutations in the UB have no effect on β3 integrin 
expression (Fig 3.6B).  
 
Figure 3.6. UB Decreases β3-Intergrin Expression, and Mutated UBs (UBV70A and UBF4A) 
have no Effect: Serum starved confluent cultures of fibroblasts were pretreated with AMD for 30 
min followed by treatment with UB (10 µg/ml) for 24 h (A). The cells were also treated with 
mutated UBs (UBV70A and UBF4A) for 24 h (B). Cell lysates were analyzed by western blot 
using anti-β3-integrin antibodies. The lower panels exhibit the mean data normalized to actin. 
*P<0.05 versus CTL; 
$
P<0.05 versus UB; n = 6-7.    
 
 VEGF-A is suggested to play a role in tissue repair (12). Recently, we have shown that 
extracellular UB increases VEGF-A expression in microvascular endothelial cells (45). Western 
blot analysis of cell lysates using anti-VEGF-A antibodies showed a significant increase in the 
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expression of VEGF-A in UB-treated (24 h) cells compared to CTL (Fig 3.7A). AMD3100 alone 
had no significant effect on VEGF-A expression. However, it almost completely inhibited UB-
mediated increases in VEGF-A expression (CTL, 1.00±0.01; UB, 3.22±0.6; AMD+UB, 
1.49±0.3, AMD, 1.15±0.1; *P<0.05 vs CTL; n = 5; 7A). Treatment of cells with mutated UBs 
had no effect on VEGF-A expression (Fig 3.7B). 
 
Figure 3.7. UB Increases VEGF-A Expression, while Mutated UBs (UBV70A and UBF4A) have 
no Effect: Serum starved confluent cultures of fibroblasts were pretreated with AMD for 30 min 
followed by treatment with UB (10 µg/ml) for 24 h (A). The cells were also treated with mutated 
UBs (UBV70A and UBF4A) for 24 h (B). Cell lysates were analyzed by western blot using anti-
VEGF-A antibodies. The lower panels exhibit the mean data normalized to actin. *P<0.05 versus 
CTL; 
$
P<0.05 versus UB; n = 6.    
 
 
Discussion 
Cardiac fibroblasts play a critical role in maintaining normal function of the heart, and in 
cardiac remodeling during pathological conditions, including hypertension and following 
myocardial infarction (42). A major finding of this study is that extracellular UB modulates 
fibroblasts phenotype and function. The data presented here shows that extracellular UB 1) 
interacts with the cell surface; 2) induces cytoskeletal rearrangement; 3) inhibits migration of 
fibroblasts into the wound and expression of β3 integrins; 4) activates intracellular signaling 
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involving ERK1/2 pathway; 5) increases VEGF-A expression. Most of the effects of UB are 
inhibited by the inhibition of CXCR-4 receptor, suggesting that involvement of CXCR-4 in 
modulation of fibroblast function and phenotype in response to extracellular UB.   
UB is a normal constituent in the plasma (47). Extracellular UB is proposed to have 
pleiotropic functions including regulation of immune response, anti-inflammatory and 
neuroprotective activities (26; 28; 36). Interaction and internalization of extracellular UB is 
shown in human peripheral blood mononuclear cells and monocytic leukemia cells. 
Inflammatory stimuli increase uptake of labelled UB suggesting the possibility that uptake of 
extracellular UB could be directed towards restoring intracellular UB equilibrium (37). 
Previously, using N-terminal biotin-labelled UB, we provided evidence for the cellular 
interaction/uptake of extracellular UB in adult rat cardiac myocytes. β-AR stimulation enhanced 
this interaction/uptake by ∼1.9-fold (41). This is the first study indicating interaction of 
extracellular UB by cardiac fibroblasts. In THP-1 cells, extracellular UB is shown to induce 
intracellular signaling, including phosphorylation of ERK1/2 and Akt (40). UB-mediated 
phosphorylation of these kinases occurred transiently which declined within 30 min. However, 
SDF-1a phosphorylation was sustained for 30 min. Furthermore, UB showed weaker 
chemotactic activity in cell migration assay when compared to SDF-1α (40). In adult rat cardiac 
myocytes, extracellular UB alone had no effect on the activation of JNKs and glycogen synthase 
kinase-3β (GSK-3β). However, it inhibited β-AR-stimulated activation of JNKs and GSK-3β 
(41).  In cardiac fibroblasts, extracellular UB and SDF-1α activated ERK1/2. However, Akt 
activation was only observed with SDF-1α. SDF-1α also binds to CXCR-7 (4). However, 
overexpression of CXCR-7 in HEK293 failed to increase UB receptor binding, suggesting that 
CXCR-7 may not serve as a receptor for extracellular UB (40).   Collectively, these data suggest 
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that the response to UB may be cell-type specific, and differential responses between UB and 
SDF-1α could be due to the involvement of receptor/s other than CXCR-4.   
Activated fibroblasts play a critical role in both the reparative and fibrotic processes. In 
normal tissues, resident fibroblasts are quiescent, producing limited amounts of extracellular 
matrix proteins and exhibiting few actin-associated cell-matrix and cell-cell contacts (48). Tissue 
injury induces alterations in the microenvironment, resulting in differentiation of fibroblasts into 
myofibroblasts (18). Myofibroblasts are characterized by the presence of microfilamentous 
contractile apparatus enriched in α-SMA  and its assembly into stress fibers (18). Formation of 
stress fibers is important for fibroblast migration (8). Immunocytochemical analysis of cells 
using phalloidin-FITC and α-SMA staining showed that intracellular UB induces structural 
changes in the cardiac fibroblasts. UB treatment enhanced polymerization of actin into the stress 
fibers. Extracellular UB also increased expression of α-SMA, a hallmark of differentiated 
fibroblasts into myofibroblasts. However, it was interesting to note the absence of filamentous 
membrane projections called filopodia or lamellipodia in UB-treated cells. UB-treated samples 
also exhibited decreased migration of fibroblasts into the wound. This finding is in contrast to 
cardiac microvascular endothelial cells where extracellular UB promotes the formation of stress 
fibers, lamellopodia and filopodia (45). Previously, we have shown that exogenous UB decreases 
β-AR-stimulated increases in myocardial fibrosis (11). UB-mediated decrease in the fibroblast 
migration into the wound may help explain decreased fibrosis in the heart during β-AR 
stimulated cardiac remodeling. However, further investigations are needed to prove this thesis. 
Integrins are cell surface receptors that play a role in cell adhesion and migration, as well 
as in growth and survival (20; 25). Fibroblasts are capable of modulating their microenvironment 
through autocrine and paracrine signaling, thereby playing a role in tissue remodeling following 
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tissue injury. Fibroblasts are also shown to play a role in the angiogenic process (32; 51). 
Fibroblasts secrete fibroblast growth factor and VEGF-A (33). VEGF-A is considered as a potent 
angiogenic inducer. In this study, we found that UB treatment increases VEGF-A expression. 
Increased expression of VEGF-A is consistent with our previous finding in microvascular 
endothelial cells where UB treatment increased VEGF-A expression (45). Cardiac fibroblasts 
express β3 integrin (17). β3 integrin is shown to play a critical role in cardiac fibroblasts 
adhesion, migration, proliferation and extracellular matrix production since β3-/- cardiac 
fibroblast exhibit a significant reduction in these processes (5). The data presented here 
demonstrates significant reduction in β3 integrin expression following UB treatment. The 
absence of filopodia and lamellopodia, and decreased expression of β3 integrins can help explain 
the reduced migration of fibroblasts into the wound in UB-treated samples. Increased expression 
of VEGF-A may act as a paracrine factor for cardiac microvascular endothelial cells to induce 
angiogenesis.   
Recently, CXCR-4 has been identified as a receptor for extracellular UB in human 
myeloid cells (38). SDF-1also calledCXCL-12) isconsidered a natural ligand for CXCR-4 
(6). SDF-1α/CXCR-4 axis is suggested to play a pivotal role in the regulation of bone marrow-
derived stem cell homing, repopulation and mobilization of stem cells into the peripheral blood 
(24). Mice lacking SDF-1α or CXCR-4 confirm the essential role of SDF-1α/CXCR-4 axis in 
hematopoiesis, cardiogenesis and vasculogenesis during embryonic development (15; 34; 46; 
57). Cardiac myocytes and non-myocyte cell populations of the heart express CXCR-4 receptors 
(9). Previously, we provided evidence for CXCR-4 as a receptor for extracellular UB in 
microvascular endothelial cells (44). Here, we provide evidence for CXCR-4 as a receptor for 
extracellular UB in cardiac fibroblasts. We show that extracellular UB co-immunoprecipitates 
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with CXCR-4. Interaction of extracellular UB with CXCR-4 was confirmed using the PLA 
technique. AMD 3100 and SDF-1α time-dependently decreased interaction of extracellular UB 
with CXCR-4 as analyzed by western blot. AMD3100 also decreased binding of FITC-labeled 
UB. It enhanced the migration of cells in the wound area, decreased activation of ERK1/2 and 
expression of VEGF-A and restored expression of β3 integrin.  Use of two different mutated UB 
proteins (F4A and V70A) on the expression of β3-integrin and VEGF-A further supports the 
involvement of CXCR-4 receptor in extracellular UB signaling. It is interesting to note that 
AMD 3100 almost completely inhibits UB-mediated increases in β3 integrins and VEGF-A 
expression. However, inhibition of ERK1/2 was partial. The reasons for this differential response 
may include differences in binding affinities for AMD 3100 and UB and/or incubation durations.  
Perspectives 
 Cardiac fibroblasts are important in maintaining the normal function of the heart as well 
as in wound repair following injury to the heart. UB is found in normal plasma. A variety of 
disease states increase levels of UB in the plasma. Here we provide evidence that extracellular 
UB modulates cardiac fibroblast function and phenotype via the involvement of CXCR-4 
receptor. Further investigation of signaling mechanisms leading to UB-mediated regulation of 
cardiac fibroblast function and phenotype may help uncover novel strategies to improve cardiac 
remodeling and function.  
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Abstract 
Exogenous ubiquitin (UB) plays an important role in β-AR-stimulated myocardial remodeling 
with effects on LV function, fibrosis and myocyte apoptosis. Extracellular UB modulates cardiac 
fibroblast function and phenotype, and increases expression of angiogenic molecules in cardiac 
microvascular endothelial cells. This study tested the hypothesis that exogenous UB plays a 
protective role in ischemia/reperfusion (I/R) injury in the heart and cardiac myocytes. Isolated 
mouse hearts underwent 15 min of baseline perfusion, 25 min of global ischemia and 40 min of 
reperfusion. UB (10 μg/ml) was infused within 5 min before ischemia. Isolated adult rat 
ventricular myocytes (ARVMs) were exposed to simulated ischemia/reperfusion by placing the 
cells in a hypoxic chamber for 2.5 h followed by reoxygenation (H/R) for indicated time points. 
Measurement of infarct size using TTC-staining showed that UB infusion significantly decreases 
infarct size. UB I/R hearts showed a significant improvement in functional recovery as measured 
by increased % left ventricular developed pressure. Activation of proapoptotic proteins, p-STAT-
1 and caspase-9, was significantly lower in UB I/R hearts when compared to I/R. In ARVMs, 
apoptosis was lower in UB H/R group when compared to H/R. Activation of Akt was higher, 
activation of GSK-3β was lower in UB H/R cells versus H/R. The number of reactive oxygen 
species and superoxide positive ARVMs was lower in UB-treated samples. TMRM staining 
showed that UB treatment increases the number of ARVMs with polarized mitochondria. 
CXCR-4 antagonist (AMD3100) significantly negated the protective effects of UB on H/R-
induced apoptosis and activation of Akt and GSK-3β. UB mutants, unable to bind to CXCR-4, 
had no effect on H/R-induced apoptosis, activation of Akt and GSK-3β and oxidative stress. 
Thus, exogenous UB, most likely acting via CXCR-4, plays a protective role in I/R injury with 
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effects on infarct size, heart function, cardiac myocyte apoptosis, ROS and intracellular 
signaling.              
Introduction 
 Myocardial ischemia/reperfusion (I/R) injury occurs from reperfusion of blood and oxygen 
in acute myocardial infarction. I/R injury increases reactive oxygen species (ROS) production 
and induces cardiac myocyte apoptosis (25; 27; 55). The apoptotic pathway involves 
mitochondrial dysfunction, which is activated in myocytes by hypoxia, ischemia/reperfusion, and 
oxidative stress (9). Mitochondria are considered as a major source of ROS and an increase in 
ROS causes mitochondrial dysfunction including a loss in mitochondrial membrane potential 
(24; 28). Mitochondrial dysfunction is a major contributor to loss of myocytes during myocardial 
ischemia and subsequent reperfusion (42). Despite advances in understanding the molecular and 
cellular mechanisms that regulate the damage caused by I/R injury, the treatment for I/R injury 
remains a challenge.    
 Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells. 
The most important intracellular function of UB is to regulate protein turnover by the ubiquitin-
proteasome pathway (17). The ubiquitin-proteasome pathway may regulate receptor 
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in 
cardiac myocytes (61). UB is a normal constituent of plasma. Elevated levels of UB are 
described in the serum or plasma of patients with parasitic and allergic diseases (4), alcoholic 
liver disease (54), type 2 diabetes (2), β2-Microglobulin amyloidosis (41) and chronic 
hemodialysis patients (3). Patients with traumatic brain injury are shown to have increased UB 
levels in the cerebrospinal fluid (37). Extracellular UB is proposed to have pleiotropic functions 
including regulation of immune response, anti-inflammatory and neuroprotective activities (36; 
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38; 43), as well as regulation of growth and apoptosis in hematopoetic cells (11). C-X-C 
chemokine receptor (CXCR-4) plays an important role in a variety of biological processes, and is 
suggested to be involved in the pathophysiology of various disease processes, such as cancer, 
HIV, ischemic myocardial injury, and angiogenesis (56). Stromal derived factor-1α (SDF-1α) is 
the cognate ligand for CXCR-4 which is implicated in homing of hematopoietic stem cells 
during wound repair (8). Interestingly, CXCR-4 has been identified as a receptor for UB in 
THP1 leukemia cell line (46). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini 
et al., provide evidence that the ubiquitin-CXCR-4 interaction follows a two-site binding 
mechanism in which the hydrophobic surfaces surrounding Phe-4 and Val-70 are important for 
receptor binding, whereas the flexible C terminus facilitates receptor activation (47). 
 Previously our lab has shown that β-adrenergic receptor (β-AR) stimulation increases 
extracellular levels of UB, and treatment of adult rat ventricular myocytes with UB inhibits β-
AR-stimulated apoptosis (49). In vivo, exogenous UB decreased β-AR-stimulated increases in 
cardiac myocyte apoptosis and myocardial fibrosis (12). Our recent work suggest that 
extracellular UB modulates cardiac fibroblast function and phenotype (unpublished work), and 
increases expression of angiogenic molecules in cardiac microvascular endothelial cells (51). 
The objective of this study was to investigate the role extracellular UB plays in I/R injury in 
isolated hearts and cardiac myocytes. The data presented here suggest that extracellular UB 
decreases infarct size, improves functional recovery of the heart, and decreases activation of 
STAT-1 and caspase-9. In ARVMs, UB treatment decreased H/R-induced myocyte apoptosis, 
activated Akt while inactivating GSK-3β, decreased oxidative stress and improved the number of 
myocytes with polarized mitochondria. Most of these effects of UB are negated by CXCR-4 
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antagonist AMD 3100. Mutated UB, unable to bind CXCR-4 had no effect on H/R-induced 
apoptosis, intracellular signaling or oxidative stress.   
 
Methods and Materials 
Vertebrate Animals 
All experiments and procedures were reviewed and approved by the East Tennessee State 
University Institutional Committee on Animal Care and conform to the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). Male C57BL/6 mice (8 to 10 week-old; Jackson Laboratories, Bar 
Harbor, ME) were used. Mice were anesthetized using a mixture of isoflurane (2.5%) and 
oxygen (0.5 l/min) and the heart was excised following a bilateral cut in the diaphragm. Animals 
were euthanized by exsanguinations. 
 
Isolated Heart Perfusion System (Langendorff) 
Langendorff global I/R experiments were performed in isolated mouse hearts as 
previously described (29). The aorta was quickly cannulated and the heart was perfused using 
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 NaCHO3, 
2.5 CaCl2, and 10.6 glucose. The buffer was equilibrated with 95% O2 and 5% CO2 and 
maintained at 37°C. A fluid-filled silicon balloon was inserted in the left ventricle through the 
mitral valve for left ventricular developed pressure (LVDP) measurement with a pressure 
transducer (AD Instruments, Dunedin, New Zealand). Hearts were allowed to stabilize during a 
15 min baseline period followed by 25 min ischemia and 40 min reperfusion. UB (10 μg/ml in 
Krebs buffer) treatment was started within 5 min before ischemia. I/R hearts received Krebs 
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buffer throughout the procedure. Immediately at the end of reperfusion, hearts were snap frozen 
with liquid nitrogen and stored at -80ºC.  
 
Infarct Size 
Infarct size was measured using tetrazolium chloride (TTC; Sigma) staining. Each heart 
was sliced transversely to yield five slices. The slices were incubated in 1% TTC for 15 min at 
37°C. Infarct size was calculated, using Bioquant image analysis software, as the percentage of 
total white area divided by the total tissue area.  
 
Cardiac Myocyte Isolation, Treatment and Hypoxia/Reoxygenation  
Calcium-tolerant ARVMs were isolated from the hearts of adult male Sprague-Dawley 
rats (150-200 g) as described previously (39). ARVMs were plated in Dulbecco’s modified 
Eagle’s medium (DMEM; Mediatech) supplemented with 25 mM HEPES, 0.2% albumin, 5 mM 
creatine, 2 mM L-carnitine, 5 mM taurine, and 0.1% penicillin-streptomycin at a density of 30–
50 cells/mm
2
 on 100-mm tissue culture dishes or coverslips (Fisher Scientific) precoated with 
laminin (1 µg/cm
2
). ARVMs were cultured overnight in the above medium. After changing the 
medium, the ARVMs were treated with UB (10 µg/ml; Sigma) or mutated UB (mUB V70 and 
mUB F4; 10μg/ml; Boston Biochem) for 30 min at 370C with 5% CO2. To simulate 
ischemia/reperfusion, ARVMs were incubated at 37°C with 5% CO2 and 0.1% O2 in a hypoxia 
chamber (Pro-Ox Model C21, BioSpherix Ltd, Redfield NY) for 2.5 h. After changing the media 
containing the corresponding treatments, ARVMs were then incubated at 37
0
C with 5% CO2 
(reoxygenation) for indicated time points. To investigate the role of CXCR-4, cells were 
pretreated with AMD 3100 for 30 min prior to UB treatment.  
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Apoptosis 
To detect apoptosis, myocytes were placed in a hypoxic chamber for 2.5 h, followed by 
18 h of reoxygenation. TUNEL-staining assay was performed using in situ death detection kit 
according to the manufacturer’s instructions (Roche Molecular Biochemicals). Hoechst 33258 
(10 µM; Sigma, St Louis, MO) staining was used to count the total number of nuclei. The 
percentage of TUNEL-positive cells (relative to total ARVMs) was determined by counting 
∼200 cells in 10 randomly chosen fields per coverslip for each experiment. 
 
Measurement of Mitochondrial Membrane Polarization  
ARVMs were plated on 50-mm MatTek dishes (MatTek, Ashland, MA) and incubated 
for 30 min in 3 ml of culture medium containing 200 nM TMRM at 37ºC and 5% CO2 (58). After 
30 min of incubation, the culture media was substituted with PBS plus 5 mM glucose and 10 mM 
succinate. Before imaging, a cover slip was placed over the cells, and 15 µl sterile oxyrase was 
added. Oxyrase selectively removes oxygen creating depletion of oxygen in the myocyte’s 
immediate surroundings. Images of cells were captured using the Zeiss AxioCam MRm 
monochrome digital camera. The number of polarized cells (i.e., those exhibiting TMRM 
fluorescence) was counted at each time point of oxyrase incubation and was expressed as a 
percent of total cells before anoxia (basal) imaged using fluorescent microscopy.  
 
ROS Detection 
ROS was detected using the Total ROS detection kit from Enzo Life Sciences and used 
according to manufacturer’s instructions. This kit is designed to directly monitor real time ROS 
production in live cells using fluorescent microscopy.  For this, UB or mutated UB treated cells 
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were exposed to hypoxia 2.5 h followed by reoxygenation for 1 h. Cells were loaded with ROS-
responsive fluorescence probe for 1 h during reoxygenation. After washing with phosphate-
buffered saline (PBS), cells were visualized using a fluorescent microscope. Superoxide staining 
appears as red dots, while ROS-positive cells exhibit green fluorescence.       
 
Western Analysis 
LV tissue lysates were prepared in RIPA buffer [10 mM Tris-HCl (pH 7.2), 158 mM 
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium 
orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride] using a tissue homogenizer. Cell lysates 
were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X-100, and 1 mM 
phenylmethylsulfonyl fluoride]. Equal amounts of total proteins (60 µg from tissue or cell 
lysates) were resolved on 10% SDS-polyacrylamide gels. The proteins were transferred onto 
PVDF membrane. The blots were then probed with primary antibodies directed against p-Akt 
(1:1000; Cell Signaling Tech.), p-GSK-3β (1:1000; Cell Signaling Tech.), caspase-9 (1:1000; 
Millipore), p-STAT-1 (1:1000; Millipore), and appropriate secondary antibodies. Membranes 
were then stripped and probed with Akt, GSK-3β, STAT-1, or actin (Chemicon) antibodies to 
normalize protein loading. Band intensities were quantified using Kodak photo documentation 
system (Eastman Kodak Co.).  
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Statistical Analysis  
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a 
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test. 
Probability (P) values of <0.05 were considered to be significant. 
 
Results 
UB Treatment Decreases I/R-induced Infarct Size and Improves Functional Recovery of the 
Heart  
To investigate if extracellular UB treatment modulates global I/R injury, isolated hearts 
were subjected to 25 min of global ischemia followed by 40 min of reperfusion in the presence 
or absence of UB. TTC staining showed a significant decrease in % infarct size in UB I/R hearts 
when compared to I/R alone (I/R, 39.5±6.9; UB I/R, 13.7±2.8*; *p<0.05 vs I/R; n= 6; Fig 4.1A). 
Left ventricular development pressure (LVDP) is a measure of cardiac performance in 
langendorff perfused hearts. UB I/R hearts showed a greater increase in % LVDP recovery 
following ischemia when compared to I/R hearts (I/R, 50.7±4.4; UB I/R, 67.3±4.3*; *p<0.05 vs 
I/R; n= 6; Fig 4.1B).  
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Figure 4.1. UB Decreases Infarct Size and Improves LVDP Recovery. Mouse hearts underwent 
global ischemia for 25 min, followed by 40 min reperfusion. A. Upper panel depicts 
representative tetrazolium chloride (TTC) stained hearts showing a decrease in infarcted region 
(white area) in UB I/R hearts. The lower bar graph exhibits % infarct size. B. Recovery of left 
ventricular developed pressure. *P<0.05 vs I/R; n = 6 hearts in each group. 
 
UB Decreases Activation of p-STAT-1 and Caspase-9 in I/R Hearts  
Proapoptotic proteins, STAT-1 and caspase-9, are activated during I/R injury (35; 52). 
Western blot analysis of heart homogenate using anti-p-STAT-1 antibodies showed a significant 
decrease in the phosphorylation of p-STAT in UB I/R group vs I/R (I/R, 0.90±0.11; UB I/R, 
0.54±0.03*; *p<0.05 vs I/R; n= 4; Fig 4.2A). Presence of ~17 kDa band on western blot using 
anti-caspase-9 antibodies indicates activation of caspase-9. Western blot analysis of heart 
homogenate showed decreased levels of active caspase-9 in UB I/R group when compared to I/R 
(I/R, 1.63±0.27; UB I/R, 0.89±0.08*; *p<0.05 vs I/R; n= 4; Fig 4.2B). 
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Figure 4.2. UB Decreases I/R-Induced Activation of STAT-1 and Caspase-9: Total heart lysates 
(60 µg) were analyzed by western blot using phospho-specific STAT-1 (A) or anti-caspase-9 
antibodies (B).  The lower panels exhibit mean data normalized to total STAT-1 or actin.  
*P<0.05 versus I/R; n = 4.  
 
UB Treatment Decreases Hypoxia/Reoxygenation-Induced Apoptosis in ARVMs 
Hypoxia for 2.5 h followed by reoxygenation for 18 h (H/R) significantly increased 
apoptosis when compared to control (CTL) cells incubated at 37
0
C with 5% CO2 (regular 
incubator). However, UB treated samples showed a significant decreases in TUNEL-positive 
ARVMs when compared to H/R. Pretreatment with AMD 3100 significantly negated the 
protective effects of UB (CTL, 3.3±0.7; H/R, 35.5±6.3*; UB H/R, 9.2±2.2
&
; AMD+UB H/R, 
34.1±4.1*
$
; AMD H/R, 24.3±5.0*; *p<0.05 vs CTL; &p<0.05 vs H/R; &p<0.05 vs UB; n = 3-4; 
Fig 4.3A). Mutated UB (mUBV70 or mUBF4) had no effect on H/R-mediated increases in the 
number of apoptotic ARVMs (CTL, 2.2±0.2; H/R, 25.7±2.3*; mUBV70 H/R, 21.0±5.4*; 
mUBF4 H/R, 21.5±2.6*; *p<0.05 vs CTL; n=3-4; Fig 4.3B).   
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Figure 4.3. UB Inhibits H/R-Induced Apoptosis in ARVMs: A. ARVMs pretreated with AMD 
3100 (AMD; 10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells 
then underwent hypoxia for 2.5 h min and reoxygenation for 18 h. *p<0.05 vs CTL; &p<0.05 vs 
H/R; &p<0.05 vs UB; n = 3-5. B. ARVMs were treated with mutated UBs (mUB V70 and mUB 
F4; 10μg/ml) for 30 min followed by H/R as described. *P<0.05 versus CTL. 
 
Activation of Akt and GSK-3β in ARVMs 
PI3-kinase activates Akt, and activation of Akt plays an anti-apoptotic role (26). Western 
blot analysis of cell lysates using phospho-specific anti-Akt antibodies showed a significant 
increase in Akt phosphorylation (activation) in UB H/R group when compared to CTL and H/R 
groups. AMD 3100 pretreatment significantly decreased UB H/R-mediated increase in Akt 
phosphorylation (CTL, 1±0.01; H/R, 1.11±0.1; UB H/R, 2.23±0.3*; AMD+UB H/R, 1.06±0.2
$
; 
*P<0.05 vs CTL and H/R; 
$
P<0.05 vs UB H/R; n = 4-6; Fig 4.4A). Treatment with mutated UB 
(mUBV70) had no effect on the phosphorylation of Akt (CTL, 1±0.01; H/R, 1.11±0.1; UB H/R, 
2.23±0.3*; mUBV70, 1.09±0.1
$
; *P<0.05 vs CTL and H/R; 
$
P<0.05 vs UB H/R; n = 4-6; Fig 
4.4B).  
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Figure 4.4. UB Activates Akt in ARVMs:  A. ARVMs were pretreated with AMD 3100 (AMD; 
10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells then 
underwent hypoxia for 2.5 h and reoxygenation for 15 min. B. ARVMs were treated with 
mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min followed by H/R for as described. 
Cell lysates (20 µg) were analyzed by western using phospho-specific anti-Akt antibodies.  The 
lower panels exhibit mean data normalized to total Akt. *P<0.05 versus H/R; 
$
P<0.05 versus UB 
H/R; n = 4-5. 
 
 Phosphorylation of an NH2-terminal serine residue (Ser
9
) inactivates GSK-3β. Akt is one 
of the upstream kinases involved in phosphorylation (Ser
9
) and inactivation of GSK-3β (22). 
Western blot analysis of cell lysates using phospho-specific (Ser
9
) anti-GSK-3β antibodies 
showed decrease phosphorylation (activation) of GSK-3β in UB H/R group when compared to 
CTL and H/R groups. AMD 3100 pretreatment significantly decreased UB H/R-mediated 
increase in Akt phosphorylation (CTL, 1.00±0.01; H/R, 1.23±0.2; UB H/R, 2.47±0.2*; 
AMD+UB H/R
$
, 1.25±0.1; *P<0.05 vs CTL and H/R, 
$
P<0.05 vs UB H/R; n = 4-6; Fig 4.5A). 
Treatment with mutated UB (mUBV70) had no effect on the phosphorylation of Akt (CTL, 
1±0.01; H/R, 1.23±0.2; UB H/R, 2.47±0.3*; mUBV70 H/R, 1.06±0.1
$
; *P<0.05 vs CTL and 
H/R; 
$
P<0.05 vs UB H/R; n = 4-6; Fig 4.5B).  
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Figure 4.5. UB Inactivates GSK-3β in ARVMs: A. ARVMs were pretreated with AMD 3100 
(AMD; 10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells then 
underwent hypoxia for 2.5 h and reoxygenation for 15 min. B. ARVMs were treated with 
mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min followed by H/R for as described. 
Cell lysates (20 µg) were analyzed by western using phospho-specific anti-GSK-3β antibodies. 
The lower panels exhibit mean data normalized to total GSK-3β. *P<0.05 versus H/R; $P<0.05 
versus UB H/R; n = 4-5. 
 
UB Treatment Decreases the Number of ROS and Superoxide-Positive Myocytes 
ROS are implicated in ischemic or hypoxic-toxicity with and without reperfusion (1; 31). 
To determine the effect UB on oxidative stress, we measured the number ROS and superoxide 
positive ARVMs following H/R. H/R increased the number of ROS-positive ARVMs when 
compared to CTL. The UB H/R group showed a significant decrease in total number of ROS-
positive ARVMs when compared to H/R. However, mutated UBs showed no significant change 
in total ROS when compared to H/R (CTL, 7.2±2.3; H/R, 54.2±7.3*; UB H/R, 11.6±2.6
$
; 
mUBF4 H/R, 52.0±5.1*; mUBV70 H/R, 57.9±3.0*; p<0.05 vs CTL; 
$
P<0.05 vs H/R; n = 4-6; 
Fig 4.6).    
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Figure 4.6. UB Decreases the Number of H/R-Induced ROS-Positive ARVMs: ARVMs were 
pretreated with UB or mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min. The cells 
then underwent hypoxia for 2.5 h followed by reoxygenation for 1 h. At time of reoxygenation, 
cells were loaded with total ROS detection stain for 1 h. Green fluorescent staining indicates 
ROS-positive ARVMs (A). B. Quantitative analysis of ROS-positive ARVMs. *P<0.05 versus 
CTL; 
$
P<0.05 versus UB H/R; n = 4-6. 
 
Previous reports have shown an increase in superoxide after reperfusion of the isolated 
ischemic heart (34; 59). Pretreatment with UB showed a significant decrease in superoxide-
positive myocytes when compared to H/R myocytes. However, mutated UBs showed no change 
in superoxide-positive ARVMs when compared to H/R (CTL, 5.6±1.3; H/R, 20.7±3.4*; UB H/R, 
7.6±2.8
$
; mUBF4 H/R, 24.6±2.8*; mUBV70 H/R, 22.3±5.2*; *P<0.05 vs CTL; 
$
P<0.05 vs H/R; 
n = 4-6; Fig 4.7).       
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Figure 4.7. UB Decreases the Number of H/R-Induced Superoxide-Positive ARVMs: ARVMs 
were pretreated with UB or mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min. The 
cells then underwent hypoxia for 2.5 h followed by reoxygenation for 1 h. At time of 
reoxygenation, cells were loaded with superoxide detection stain for 1 h. Red fluorescent 
staining indicates superoxide-positive ARVMs (A).  B. Quantitative analysis of superoxide-
positive ARVMs. *P<0.05 versus CTL; 
$
P<0.05 versus UB H/R; n = 4-6. 
 
UB Treatment Protects Mitochondrial Polarization  
H/R induces mitochondrial damage, including loss of membrane potential (13). To 
investigate if UB treatment protects mitochondrial polarization, ARVMs were subjected to 
anoxia. Mitochondrial polarization was monitored with TMRM potentiometric dye for 105 min 
under these conditions. We found a trend towards maintained mitochondrial polarization 60 min 
after UB treatment. However, the number of ARVMs with polarized mitochondria was 
significantly greater in UB-treated samples 105 min after UB treatment (Fig 4.8).        
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Figure 4.8. UB Treatment Helps Maintain Mitochondrial Membrane Polarization: ARVMs were 
incubated with oxyrase to create anoxic conditions. Mitochondrial membrane polarization was 
measured using TMRM loading. Upper panel depicts images of ARVMs obtained using 
fluorescent microscope before anoxia (basal) and at indicated time points during anoxia. The 
number of polarized cells (i.e., those exhibiting TMRM fluorescence) was counted at each time 
point of oxyrase incubation and was expressed as a percent of total cells before anoxia (basal), 
and are expressed as means ± SE (n = 6). *P<0.05 vs CTL. 
 
 
Discussion 
Previously, we provided evidence that β-AR stimulation increases levels of extracellular 
UB and that treatment with UB plays a protective role in β-AR-stimulated apoptosis in ARVMs 
(49). I/R injury induces cardiac myocyte apoptosis (18). A major finding of this study is that 
extracellular UB plays a protective role in I/R-induced injury in the heart, and cardiac myocytes 
apoptosis. The data presented here suggest that UB treatment decreases I/R-induced increases in 
infarct size while improving functional recovery of the heart following ischemia. These changes 
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in the heart associate with decreased activation of STAT-1 and caspase-9. In isolated ARVMs, 
UB decreased H/R-induced apoptosis. It activated Akt and decreased the number of ROS- and 
superoxide-positive ARVMs. UB treatment also helps maintain mitochondrial membrane 
polarization under anoxic conditions.  Most of the effects of UB were negated by inhibition of 
CXCR-4 receptor, while mutated UB had no effect.  
The primary pathological expression of coronary artery disease is myocardial injury 
resulting from an I/R insult (45). Cardiac myocytes are highly aerobic cells, and almost all of 
their energy production comes from oxidative phosphorylation under normal conditions (50). It 
is clear that production of ROS during both ischemia and reperfusion is a major factor 
contributing to I/R-induced cardiac injury (14; 15). Global I/R injury is known to cause 
myocytes apoptosis and create an infarcted region (19). Here we show UB treatment decreased 
infarct size in isolated hearts when compared to I/R treated hearts. UB treatment also improved 
LVDP recovery after ischemia.  
Previous studies have characterized a proapoptotic effect of STAT-1 by the upregulation 
of caspase-1 and proapoptotic genes such as FAS, FAS ligand, p21, and p53 (7; 32). Increased 
STAT-1 activation is reported to impair myocardial performance (23). Mitochondrial damage 
and leakage of cytochrome c leads to the activation of caspase-9 (53). Caspase-9 is expressed at 
high levels in the heart and is implicated in mitochondrial-mediated apoptosis (30). The 
apoptotic cascade is initiated by mitochondrial damage and activation of caspase-9 (48). 
Caspase-9 is activated during ischemia and remains activated throughout reperfusion in the intact 
rat heart (48). Activated caspase-9 is detected ~ 17 kDa band on SDS-PAGE. Here, we show that 
treatment with UB decreases the activation of STAT-1 and caspase-9. These data supports the 
previous findings of activation of STAT-1 and caspase-9 during I/R injury, and suggest that UB-
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mediated decrease in the activation of these molecules may ultimately help preserve heart 
function.   
Apoptosis of cardiac myocytes is identified as an important process in the progression to 
heart failure (57). Apoptosis contributes, with necrosis, to the cardiac cell loss after I/R injury 
(48). Using isolated ARVMs, we provide evidence that UB decreases H/R-mediated increases in 
the number of apoptotic ARVMs. Akt, a central regulator of myocyte survival, is shown to 
protect myocytes against I/R injury in the mouse heart (16). Several upstream regulators are 
reported to turn off the activity of GSK-3β, among those Akt is a well-characterized Ser/Thr 
kinase phosphorylating GSK-3β. Akt phosphorylates GSK3β (Ser-9), and this residue lies in a 
typical Akt consensus substrate motif (40). Previously, we have shown that activation of GSK-3β 
plays a pro-apoptotic role in β-AR-stimulated cardiac myocyte apoptosis (39). Exogenous UB 
inhibited β-AR-stimulated activation of GSK-3β and apoptosis in vitro and in vivo (12; 49). The 
data presented here demonstrate that UB activates Akt and inhibits activation of GSK-3β within 
10 min after reoxygenation. Collectively, these data suggest that activation of Akt signaling 
pathway may be a key signaling event involved in protecting cardiac myocytes against apoptosis. 
Inhibition of GSK-3β attenuates I/R injury by inhibiting mitochondrial permeability transition 
pore (mPTP) opening (60). Therefore, it is possible that extracellular UB may inhibit cardiac 
myocyte apoptosis by maintaining normal mitochondrial function via the involvement of 
AKT/GSK-3β pathway/s.  
Low to moderate levels of superoxide are produced during ischemia, followed by a burst 
of ROS production at the onset of reperfusion (5; 33). The cardiac myocyte sarcolemma contains 
numerous uniport and antiport ion channels along with active transport mechanisms that are 
required to maintain cellular pH and membrane potential (44; 50). Evidence has been provided 
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that mitochondria serve as the final arbitrators of life or death during an I/R insult. These 
organelles are not only required to produce ATP, but they can also trigger both necrosis and 
apoptosis (20).  Free radicals are produced within minutes of reperfusion and continue to be 
generated for hours after the restoration of blood flow to ischemic tissue (6). Oxidant-mediated 
cellular injury can lead to damage in the cell membrane, impairment of the cell's ability to 
regulate ionic homeostasis, and contribute to mitochondrial injury, leading to a decrement in 
oxidative phosphorylation and opening of the mPTP (33). The influx of hydrogen ions into the 
mitochondria during hypoxia dissipates the mitochondrial membrane potential (Δψm) and 
activates the Na
+–H+ exchanger (NHE) causing an elevation in sodium levels. To reduce the 
levels of Na
+
 in the mitochondria, the sodium–calcium exchanger (Na+–Ca2+ exchanger) is 
activated, thus introducing Ca
2+
 into the mitochondria. Upon reperfusion, the Na
+–Ca2+ 
exchanger is reversed and starts extruding Ca
2+
 from mitochondria (21). It is clear that 
mitochondrial dysfunction is a major contributor to loss of myocytes during myocardial ischemia 
and subsequent reperfusion. With a reduced number of myocytes, the heart is no longer able to 
sustain contractility and heart failure develops (42). Here we show extracellular UB decreases 
the ROS and superoxide-positive ARVMs during H/R. It also increases the number of ARVMs 
with polarized mitochondria during anoxic conditions. It should be noted, however, that a 
significant difference in CTL and UB treatment was only observed 105 min after UB treatment. 
The treatment time points should be extended beyond 105 min to observe the protective effect of 
UB in preservation of mitochondrial polarization.  
 Cardiac myocytes and non-myocyte cell populations of the heart express CXCR-4 
receptors (10). In leukemia cell line, CXCR-4 is identified as a receptor for UB (46). UB-CXCR-
4 interaction follows a two-site binding mechanism in which the hydrophobic surfaces 
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surrounding Phe-4 and Val-70 are important for receptor binding (47). Previously, we have 
shown that the CXCR4 antagonist, AMD3100, inhibits UB-stimulated increases in capillary 
network formation, suggesting involvement of CXCR4 receptor for intracellular signaling in 
endothelial cells of the heart in response to UB (51). In this study, we show that AMD 3100 
negates the effects of UB treatment with respect to apoptosis and activation of Akt and GSK-3β, 
suggesting involvement of CXCR-4 in UB signaling. Use of two different UB mutants further 
supports the involvement of this receptor in anti-apoptotic signaling pathway induced by UB.      
 
Perspectives 
UB is found in normal plasma and is elevated in many diseased states. Previously, we 
have shown that extracellular UB plays an anti-apoptotic role in β-AR-stimulated cardiac 
myocyte apoptosis in vitro and in vivo (12; 49). The data presented here suggest a protective role 
for extracellular UB in I/R-induced cardiac injury and myocyte apoptosis. In the heart, UB 
treatment improved functional recovery and decreased activation of STAT-1 and caspase-9 
during I/R injury. In vitro, UB treatment activated Akt an anti-apoptotic kinase and decreased 
H/R-induced myocyte apoptosis. The data presented here also suggests an important role for 
extracellular UB/CXCR4 axis in modulation of oxidative stress and mitochondrial membrane 
potential. Further identification of signaling mechanisms leading to UB-mediated regulation of 
I/R injury and cardiac myocyte apoptosis may uncover novel strategies to improve cardiac 
remodeling and function.  
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CHAPTER 5 
CONCLUSION 
 Significant attention is being paid to the development of therapeutics for the treatment 
and prevention of ischemia/reperfusion (I/R) injury and myocardial infarction (MI). Clinical 
trials are currently underway using therapeutic agents to reduce the adverse effects of cardiac 
remodeling caused by I/R injury and MI. Many therapeutic agents and new delivery methods are 
currently being investigated to reduce cardiac myocyte apoptosis and fibrosis. The future 
development of therapy directed at pathologic and therapeutic I/R injury and MI is dependent 
upon a clear understanding of the factors that regulate adverse remodeling of the heart and their 
mechanism of action.     
 Cardiovascular disease is the major cause of morbidity and mortality in the United States. 
I/R injury and MI cause adverse cardiac remodeling leading to a decrease in cardiac function. 
Cardiac myocytes and resident fibroblast are arguably 2 of the most import cell types of the 
heart. Due to the limited mitotic capacity of adult cardiac myocytes, it is important to find ways 
to reduce the loss of myocytes during or after injury to the heart. Fibroblasts play a significant 
role in wound repair and replacing the loss of myocytes with fibrotic tissue. Collectively, the loss 
of cardiac myocytes due to apoptosis and replacement with scar tissue causes the heart to 
become stiff reducing the functioning capacity. One way to repair the myocardium would be to 
slow or stop the loss of cardiac myocytes and reduce the deposition of fibrotic scar tissue. 
Therefore, the foundation for successful therapeutic interventions in I/R injury and MI may lie in 
the field of cardiac myocyte apoptosis and cardiac remodeling.      
 Cardiac sympathetic nerve activity increases following I/R injury and MI (Jardine and 
others 2005). Prolonged stimulation of the β-adrenergic neurohormonal axis contributes to the 
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progression of heart failure
 
and mortality in animal models and human patients (Fowler and 
others 1986; Singh and others 2001). Stimulation of β-adrenergic receptor (β-AR) increases 
expression and activity of matrix metalloproteinase (MMP-2 and MMP-9) in cardiac myocytes in 
vitro and in vivo (Menon and others 2005; Krishnamurthy and others 2007). It also induces 
apoptosis in cardiac myocytes in vitro and in vivo (Shizukuda and others 1998; Iwai-Kanai and 
others 1999; Zaugg and others 2000; Singh and others 2001). β-AR-stimulated apoptosis in 
ARVMs is demonstrated to occur via the GSK-3β-/JNK-dependent mitochondrial death pathway 
(Remondino and others 2003; Menon and others 2007).  
Ubiquitin is a highly conserved protein ~ 8.5 kDa and is found in all eukaryotic cells. 
Since UBs discovery over 3 decades ago, research has focused on UB’s role inside the cell. To 
date, the most important function of UB is the regulation of protein turnover by the ubiquitin-
proteasome pathway (Goldberg 2003). However, UB is a normal constituent of plasma and 
elevated levels of UB are described in several pathological conditions (Asseman and others 
1994; Takagi and others 1999; Akarsu and others 2001a; Akarsu and others 2001b). Previously, 
our lab has provided evidence that stimulation of β-AR receptors increases extracellular levels of 
UB in adult rat ventricular myocytes (ARVMs), and extracellular UB plays a protective role in β-
AR-stimulated apoptosis via the inactivation of GSK-3β and JNK pathways (Singh and others 
2010). However, the role extracellular UB plays in hypoxia/reoxygenation-induced cardiac 
myocyte apoptosis and remodeling has not been elucidated.        
 The data presented in this study establish a role for extracellular UB in cardiac myocyte 
apoptosis and myocardial remodeling following chronic β-AR stimulation in the heart. We found 
that exogenous UB plays an important role in β-AR-stimulated myocardial remodeling with 
effects on left ventricular function, fibrosis and myocyte apoptosis. The signal transduction 
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pathways described within for extracellular UB are depicted in Figure 5.1. We confirm our 
previous finding of an antiapoptotic function for UB in vivo and show that UB plays an 
important role in β-AR-stimulated myocardial remodeling with effects on left ventricular 
function, fibrosis, and myocyte apoptosis. Exogenous UB enhanced activation of antiapoptotic 
kinase Akt, while decreasing the activation of proapoptotic kinases, GSK-3β and JNKs.     
 
Figure 5.1 Signal Transduction Pathways for Extracellular UB in β-AR-Stimulated Apoptosis 
and Fibrosis. β-AR, β-adrenergic receptor; eUB, extracellular ubiquitin. 
 
 Cardiac fibroblast play a critical role in maintaining the normal function of the heart, and 
in the remodeling process of the heart that occurs in response to myocardial infarction (Souders 
and others 2009). In this study, chronic β-AR-stimulation increased protein levels of MMP-2, 
MMP-9, and TIMP-2. In isolated cardiac fibroblast, UB enhanced expression of MMP-2 and 
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TIMP-2. UB activated Akt and inhibition of Akt decreased MMP-2 expression. We also present 
evidence that extracellular UB modulates cardiac fibroblast phenotype and function and 
define a role CXCR4 receptor plays in modulating fibroblast phenotype and function in 
response to extracellular UB. UB interacts with fibroblast and CXCR4 receptors, induces 
cytoskeletal reorganization, induces intracellular signaling of ERK1/2, and inhibits migration of 
fibroblast into the wound. The fibroblast migration may be because UB decreases expression of 
β3 integrin, a protein involved in fibroblast migration. This may explain the reduction of fibrosis 
in UB treated β-AR-stimulated hearts.    
 Apoptosis is programmed cell death and is very organized. It has been reported that after 
MI or ischemic event, left ventricular (LV) dysfunction occurs, in part, as a result of ongoing 
cardiac myocyte apoptosis (Sharov and others 1996). Cardiac myocyte apoptosis occurs at an 
increased rate after injury due to I/R and MI (Olivetti and others 1997). However, the 
mechanisms of cardiac myocyte apoptosis leading to remodeling are not fully understood. In this 
study, we present evidence that extracellular UB plays a role in I/R injury in isolated hearts and 
cardiac myocytes. The data suggest extracellular UB protects the heart by decreasing infarct 
size, improving functional recovery of the heart, and decreasing activation of STAT-1 and 
caspase-9. In vitro, UB treatment decreases H/R-induced myocyte apoptosis, activates Akt 
while inactivating GSK-3β, decreases oxidative stress and improves the number of 
myocytes with polarized mitochondria. Most of these effects of UB are negated by CXCR-4 
antagonist AMD 3100. Mutated UB, unable to bind CXCR-4 has no effect on H/R-induced 
apoptosis, intracellular signaling, or oxidative stress. Collectively, the data presented in this 
study shows evidence that extracellular UB modulates chronic β-AR-stimulated myocardial 
remodeling, fibroblast function, and I/R injury in isolated hearts and myocytes. 
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 Possible future directions for this field of study are numerous. The current study 
examined the role of exogenous UB 7 days after chronic β-AR stimulation. This time point 
should be extended beyond 7 days to investigate if UB continues to decrease cardiac 
myocyte apoptosis, fibrosis, and sustain myocardial function. Analysis of components of 
extracellular matrix, including collagen type I and IV, laminin, fibronectin, etc. may provide 
insight into the modulation of heart function in the presence of exogenous UB. In isolated 
fibroblast, AMD 3100 almost completely inhibits UB-mediated increases in β3 integrins and 
VEGF-A expression. However, inhibition of ERK1/2 was partial. Further investigation should be 
carried out to determine if this differential response is caused by differences in binding affinities 
for AMD 3100 and UB or incubation durations. The langendorff global I/R injury is a good 
model to remove any potential confounding effects derived from systemic actions of the heart. 
However, the next logical step for I/R injury model would be to move into an animal model of 
I/R injury. All the current findings have been executed using extracellular UB as a pretreatment 
before insult. It would be interesting to see if extracellular UB has the same effects postinsult to 
the heart. Further identification of signaling mechanisms leading to UB-mediated regulation of 
I/R injury and cardiac myocyte apoptosis may uncover novel strategies to improve cardiac 
remodeling and function. The structural changes related to cardiac myocyte apoptosis and 
extracellular matrix play a significant role in modulation of myocardial function and in the 
progression to heart failure. Therefore, elucidation of processes that can shift the balance from 
myocyte apoptosis to survival may have clinical implications.   
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